Clinical trials appendix Q1 2016 update The following information about AstraZeneca clinical trials in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding of key aspects of ongoing clinical programmes and is correct to the best of the Company’s knowledge as of 31 March 2016, unless otherwise specified.

It includes estimated timelines with regards to trial completion and first external presentations of primary data. These estimates are subject to change as programmes recruit faster or slower than anticipated.

Project postings on clinicaltrials.gov are updated on a continuous basis as projects progress. For the most up to date information on our clinical programmes please visit clinicaltrials.gov.

2 List of abbreviations

AEs Adverse Events LCM Lifecycle Management Q3W Every Three Weeks ASA Acetylsalicylic Acid LPCD Last Patient Commenced Dosing Q4W Every Four Weeks BiD Twice Daily MAD Multiple Ascending Dose trial Q8W Every Eight Weeks CE Clinically Evaluable MDI Metered Dose Inhaler QD Once Daily cMITT Clinical Modified Intent-To-Treat population MITT Modified Intent-To-Treat population SAD Single Ascending Dose trial DLT Dose Limiting Toxicity Microbiological Modified Intent-To- SC Sub-cutaneous mMITT Treat population FEV Forced Expiratory Volume TiD Three Times a Day MTD Maximum Tolerated Dose FPD First Patient Dosed TOC Test of Cure MTX Methotrexate HIF- Hypoxia-inducible factor prolyl hydroxylase XR Extended Release PHI inhibitor NME New Molecular Entity ICS Inhaled Corticosteroid OLE Open Long Term Extension IM Intra-muscular ORR Objective Response Rate IR Immediate Release OS Overall Survival IV Intra-venous PARP Poly ADP ribose polymerase LABA Long Acting Beta Agonist PFS Progression Free Survival LAMA Long Acting Muscarinic Agonist Q2W Every Other Week

3 Movement since Q4 2015

New to Phase I New to Phase II New to Pivotal Study New to Registration

NMEs NMEs NMEs AZD5634 MEDI3902¶ AZD3293# BACE Alz inhaled ENaC cystic fibrosis Psl/PcrV pseudomonas Beta secretase inhibitor Alzheimer’s disease MEDI9314 MEDI4166 IL4R atopic dermatitis PCSK9/GLP-1 diabetes/cardiovascular MEDI0700# BAFFl/B7RP1 systemic lupus erythematosus AZD5718 FLAP CAD MEDI7352 NGF/TNF bispecific mAb osteoarthritis pain

Additional indications durvalumab# + monalizumab PD-L1 + NKG2a mAb solid tumours durvalumab# + MEDI9447 PD-L1 + CD73 mAb solid tumours

Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration

NMEs NMEs NMEs AZD5312# tremelimumab¶ DETERMINE Bevespi Aerospace (PT003 GFF) PINNACLE androgen receptor inhibitor solid tumours CTLA-4 mAb mesothelioma LABA/LAMA COPD AZD8835 abrilumab# PI3 kinase alpha inhibitor solid tumours alpha(4)beta(7) mAb Crohn’s disease / ulcerative colitis AZD8999 MABA COPD

Additional indications Additional indications inebilizumab (MEDI-551# + rituximab) Tagrisso AZD9291 + durvalumab# CAURAL CD19 mAb + CD20 mAb haematological malignancies ≥2nd-line advanced EGFRm T790M NSCLC Brilinta/Brilique SOCRATES P2Y12 receptor antagonist outcomes trial in patients with stroke or TIA # Collaboration ¶ Registrational Phase II/III study

4 Q1 2016 New Molecular Entity (NME)1 Pipeline

RIA CVMD Oncology Infection, Neuroscience, Gastrointestinal

1 Includes significant fixed-dose combination projects, and parallel indications that are in a separate therapy area (See LCM chart for other parallel indications and oncology combination projects) # In collaboration; ¶ Registrational P2/3 study; MEDI-550 does not count toward late-stage NME totals (submitted to EMEA December 2015) Q1 2016 Lifecycle Management (LCM)1 Pipeline

RIA CVMD Oncology Infection, Neuroscience, Gastrointestinal

1 Includes significant LCM projects and parallel indications for assets in P3 or beyond. Excludes LCM projects already launched in a major market # In collaboration; ¶ Registrational P2/3 study; Ɣ MedImmune-sponsored study in collaboration with Innate Pharma AstraZeneca

Lifecycle management (new uses of existing medicines) Lifecycle management Late-stage development Early development - IMED Symbicort (ICS/LABA) Early development - MedImmune Mild asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Patients in need of GINA N = 3,750 • Arm 1: Symbicort Turbuhaler 160/4.5 μg 'as needed' + • Well-controlled asthma weeks • FPD: Q4 2014 SYGMA1 step-2 treatment Placebo Pulmicort Turbuhaler 200 μg bid • Time to first severe asthma exacerbation • LPCD: 2017 • Arm 2: Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg • Time to first moderate or severe asthma • Estimated completion: 2017 NCT02149199 Turbuhaler 'as needed' exacerbation • Estimated top-line results: 2017 • Arm 3: terbutaline Turbuhaler 0.4 mg 'as needed' + placebo • Average change from baseline in Pulmicort 200 μg Turbuhaler bid pre-dose FEV1

Global trial – 19 countries

Phase III Patients in need of GINA N = 4,114* • Arm 1: Symbicort Turbuhaler 160/4.5 μg 'as needed' + • Annual severe asthma exacerbation rate • FPD: Q1 2015 SYGMA2 step-2 treatment Placebo Pulmicort Turbuhaler 200 μg bid • Time to first severe asthma exacerbation • LPCD: 2017 • Arm 2: Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg • Average change from baseline in pre- • Estimated completion: 2017 NCT02224157 Turbuhaler 'as needed' dose FEV1 • Estimated top-line results: 2017 • Time to trial specific asthma related Global trial – 25 countries discontinuation

* There will be a blinded review for event rate which means that the final number of patients is uncertain until this review has taken place. 8 Lifecycle management Late-stage development Early development - IMED Eklira/Tudorza (LAMA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IV Patients with COPD N = 224 • Arm 1: Aclidinium bromide 400 μg • Change from baseline in Overall E-RS • FPD: Q1 2015 • Arm 2: Placebo to aclidinium bromide 400 μg Total score (i.e. score over the whole 8 • LPCD: Q3 2015 NCT02375724 weeks trial period) Global trial – five countries • Change from baseline in Overall E-RS • Clinically completed Partnered: Menarini Cough and Sputum domain score • Change from baseline in the LCQ Total • Top-line results released Q1 2016 score at Week 8. Average change from baseline in pre-dose FEV1 • Estimated completion date: Q2 2016

Phase IV Patients with moderate to very N = 4,000 • Arm 1: Aclidinium bromide 400 μg • Time to first Major Adverse • FPD: Q4 2013 ASCENT severe COPD • Arm 2: Placebo to aclidinium bromide 400 μg Cardiovascular Event (MACE). Up to 36 • LPCD: H2 2016 months NCT01966107 Global trial – two countries • Rate of moderate or severe COPD • Estimated completion date: 2018 exacerbations per patient per year Partnered: during the first year of treatment. Forest/Actavis • Rate of hospitalisations due to COPD exacerbation per patient per year during the first year of treatment • Time to first MACE or other serious cardiovascular events of interest. Up to 36 months

Phase IV Patients with stable moderate N = 30 • Arm 1: Aclidinium bromide 400 μg • Change from baseline in normalised • FPD: Q2 2014 and severe COPD • Arm 2: Placebo to Aclidinium bromide 400 μg FEV1. Week 3. FEV1 over the 24-hour • LPCD: Q1 2015 NCT02153489 period (AUC0-24) will be measured Local trial – one country following morning administration • Top-line results: Q4 2015 Partnered: • Adverse events. Week 5. A follow up Almirall telephone call will be made 14 days • Estimated completion date: H2 2016 after the last trial drug administration (for completed patients) or premature discontinuation visit (when applicable) to record adverse events

9 Lifecycle management Late-stage development Early development - IMED Duaklir (LAMA/LABA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IV Patients with moderate to N = 268 • Arm 1: Aclidinium/formoterol FDC 400/12 μg • Change from baseline in trough • FPD: Q2 2015 ACTIVATE COPD • Arm 2: Placebo to aclidinium/formoterol FDC 400/12 μg Functional Residual capacity after 4 • LPCD: Q2 2016 weeks of treatment NCT02424344 Global trial – five countries • Change from baseline in Endurance • Estimated completion date: H2 2016 Time (ET) during constant work rate CO-FUNDED: Menarini cycle ergometry to symptom limitation at 75% of Wmax after 8 weeks of treatment • Percentage of inactive patients (<6000 steps per day) after 8 weeks on treatment

10 Lifecycle management Late-stage development Early development - IMED Daliresp (oral PDE4 inhibitor) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IV COPD N = 2,354 • 52W, randomised, DB with Daliresp 500µg OD vs placebo, in • Rate of moderate or severe COPD • Completed: Q1 2016 RESPOND COPD on top of ICS/LABA exacerbations per subject per year • Estimated results: H2 2016

NCT01443845

Phase IV COPD N = 1,323 • 12W, randomised, DB to evaluate tolerability and PK of • Percentage of participants prematurely • Completed: Q3 2015 OPTIMIZE Daliresp 500 μg OD with an up-titration regimen during the first discontinuing study treatment for any • Estimated results: H2 2016 4Ws, including an open label down-titration evaluating reason during the main period NCT02165826 tolerability and PK of 250µg Roflumilast OD in subjects not tolerating 500 μg OD

Phase IIIb COPD N = 158 • 16W, randomised, placebo-controlled, DB, parallel-group trial • Number of inflammatory cells CD8+ in • Completed: Q1 2016 ROBERT to assess the anti-inflammatory effects of Roflumilast in COPD bronchial biopsy tissue specimen (sub- • Estimated results: H2 2016 mucosa) measured at randomisation NCT01509677 and at the end of the intervention period

11 Lifecycle management Late-stage development Early development - IMED Zurampic (lesinurad) (SURI, URAT1 inhibitor) Early development - MedImmune Gout

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Gout previously enrolled in N = 717 • Zurampic 200 or 400 mg QD • Assess the long-term efficacy and safety • FPD: Q1 2013 RDEA594-306 CLEAR studies Phase III RDEA594- All patients: SOC allopurinol QD of Zurampic in combination with • Trial ongoing Extension 301 & -302 (CLEAR 1 & 2) allopurinol • LPCD: 2017 trials Protocol amended Oct 2015: All patients to receive Zurampic NCT01808131 treatment dose of 200 mg QD in combination with their allopurinol

Phase III Gout previously enrolled in N = 196 • Zurampic 200 or 400 mg QD • Assess the long-term efficacy and safety • FPD: Q1 2013 RDEA594-307 CRYSTAL Phase III RDEA594-304 All patients: febuxostat 80 mg QD of Zurampic in combination with • Trial ongoing Extension (CRYSTAL) trial febuxostat • LPCD: 2017 Protocol amended Oct 2015: All patients to receive Zurampic NCT01808144 treatment dose of 200 mg QD in combination with their febuxostat

Phase II Gout previously enrolled in N = 87 • Zurampic 200, 400, or 600 mg QD • Assess the long-term efficacy and safety • FPD: Q1 2011 RDEA594-203 Open-label Phase II RDEA594-203 trial All patients: SOC allopurinol QD of Zurampic in combination with • Trial ongoing Extension allopurinol • LPCD: H2 2016 Protocol amended Oct 2015: All patients to receive Zurampic NCT01001338 treatment dose of 200 mg QD in combination with their allopurinol

12 Lifecycle management Late-stage development Early development - IMED Lesinurad/allopurinol FDC Early development - MedImmune (SURI, URAT1 inhibitor/XOI inhibitor) Gout

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy Male Subjects N = 124 Cohort 1: cross-over, rel. BA • Assess the bioavailability of • FPD: Q4 2015 RDEA594-501 Randomised, Tx. 1: lesinurad/allopurinol 200/300 FDC lesinurad/allopurinol 200/300 FDC and • LPCD: Q2 2016 Open-label, cross-over, Tx. 2: coadministered lesinurad 200mg + allopurinol 300mg lesinurad/allopurinol 200/200 FDC relative bioavailability tablets relative to coadministered NCT02581553 Cohort 2: cross-over, Food Effect, BA lesinurad and allopurinol tablets in Tx. 1: lesinurad/allopurinol 200/300 FDC (fasted) healthy adult male subjects Tx. 2: lesinurad/allopurinol 200/300 FDC (fed – high fat meal) • To assess the effect of a high fat/high calorie meal on the pharmacokinetics of Cohort 3: cross-over, rel. BA lesinurad/allopurinol 200/300 FDC Tx. 1: lesinurad/allopurinol 200/200 FDC Tx. 2: coadministered lesinurad 200mg + allopurinol 200mg tablets in healthy adult male subjects

13 Lifecycle management Late-stage development Early development - IMED Bevespi Aerosphere (PT003, LABA/LAMA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Moderate to very severe N = 2,103 Treatment (24-week Treatment Period) • Change from baseline in morning pre- • FPD: Q2 2013 PINNACLE 1 COPD • Arm 1: GFF MDI (Bevespi Aerosphere) 14.4/9.6 μg BiD dose trough FEV1 • LPCD: Q3 2014 • Arm 2: GP MDI (PT001) 14.4 μg BiD • Top-line results: Q1 2015* NCT01854645 • Arm 3: FF MDI (PT005) 9.6 μg BiD • Arm 4: Open-label tiotropium bromide * Clinically completed inhalation powder 18 μg QD • Arm 5: Placebo MDI BiD Multicentre, randomised, double-blind, parallel-group, chronic dosing, placebo- and active- controlled Estimated time from FSFV to DBL is approximately 21 months. US, Australia, New Zealand

Phase III Moderate to very severe N = 1,618 Treatment (24-week Treatment Period) • Change from baseline in morning pre- • FPD: Q3 2013 PINNACLE 2 COPD • Arm 1: GFF MDI (Bevespi Aerosphere) 14.4/9.6 μg BiD dose trough FEV1 • LPCD: Q3 2014 • Arm 2: GP MDI (PT001) 14.4 μg BiD • Top-line results: Q2 2015* NCT01854658 • Arm 3: FF MDI (PT005) 9.6 μg BiD • Arm 4: Placebo MDI BiD * Clinically completed Multicentre, randomised, double-blind, parallel group, chronic dosing and placebo-controlled Estimated time from FSFV to DBL is approximately 20 months. US

Phase III Moderate to very severe N = 850 Treatment (28-week Treatment Period) • Overall safety, tolerability and efficacy • FPD: Q4 2013 PINNACLE 3 COPD • Arm 1: GFF MDI (Bevespi Aerosphere) 14.4/9.6 μg BiD • LPCD: Q3 2014 • Arm 2: GP MDI (PT001) 14.4 μg BiD • Top-line results: Q2 2015* NCT01970878 • Arm 3: FF MDI (PT005) 9.6 μg BiD • Arm 4: Open-label tiotropium bromide inhalation powder QD Multi-centre, randomised, double-blind, parallel-group and active- * Clinically completed controlled Estimated time from FSFV to DBL is approximately 16 months. US, Australia, New Zealand

14 Lifecycle management Late-stage development Early development - IMED Bevespi Aerosphere (PT003, LABA/LAMA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIIb Moderate to severe COPD N = 150 Treatment (5- to 6- week Treatment Period) • Percentage of devices where number of • FPD: Q4 2014 (Dose Indicator trial) • GFF 14.4/9.6 µg actuations as counted at the end of the • LPCD: Q4 2014 • Placebo MDI BID trial using dose indicator reading is • Top-line results: Q1 2015* NCT02268396 Open-label and multiple-centre consistent (± 20 actuations) with number of actuations reported by subject * Clinically completed Estimated time from FSFV to DBL is approximately 11 weeks, US

Phase IIIb Moderate to severe COPD N = 40 Treatments (8-week Treatment Period) • FEV1 AUC0-24 on Day 29 • FPD: Q1 2015 (24 Hr Lung Function • GFF MDI 14.4/9.6 µg BID • LPCD: Q1 2015 Placebo) • Placebo MDI BID • Top-line results: Q3 2015 Randomised, 2-period, 2-treatment Double-blind, Multi-centre NCT02347085 and Crossover * Clinically completed

Estimated time from FSFV to DBL is approximately four months, US

Phase IIIb Moderate to severe COPD N = 80 Treatments ( 12-week Treatment Period) • FEV1 AUC0-24 on Day 29 • FPD: Q1 2015 (24 Hr Lung Function Active) • GFF MDI 14.4/9.6 µg BID • LPCD: Q2 2015 • Placebo • Top-line results: Q3 2015 NCT02347072 • Spiriva Respimat 5 µg QD (open-label) Randomised and 3-way cross-over * Clinically completed

Estimated time from FSFV to DBL is approximately six months, US

Phase III Moderate to severe COPD N = 60 Treatments ( 2 week treatment Period) • Change from morning pre-dose trough • FPD: Q2 2015 (Spacer trial) • GFF MDI 14.4/9.6 µg with a spacer FEV1 GFF 14.4/9.6 µg with • LPCD: Q1 2016 • GFF MDI 14.4/9.6 µg without a spacer Aerochamber Plus VHC relative to • Estimated top-line results: Q2 2016 Randomised, 7-day, cross-over in subjects with moderate to GFF14.4µg w/o Aerochamber Plus VHC NCT02454959 severe COPD on Day 8 • PK parameters at all doses will include Estimated time from FSFV to DBL is approximately nine months, Cmax, AUC0-12, AUC0-t, tmax, Other US PD/PK parameters may be calculated, as appropriate

15 Lifecycle management Late-stage development Early development - IMED Bevespi Aerosphere (PT003, LABA/LAMA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design (G = glycopyrronium, F = formoterol fumarate) Endpoints Status

Phase III Moderate to very severe N = 1,614 Treatments (24-week Treatment Period) • For the US/China approach, the primary • FPD: Q2 2015 (Asia Pacific trial) COPD • GFF 14.4/9.6 µg (N=514) endpoint will be the change from • LPCD: Q2 2016 • GP 14.4 µg (N=440) baseline in morning pre-dose trough • Estimated top-line results: 2017 NCT02343458 • FF 9.6 µg (N=440) FEV1 at Week 24 of treatment • Placebo (N=220) • For the Japan approach, the primary • US/China: Trough FEV1 at Week 24 of treatment endpoint will be the change from • EU/Hybrid: Co-primary= Trough FEV1 over Week 24 of baseline in morning pre-dose trough treatment and TDI score over 24 weeks FEV1 over Weeks 12 to 24 of treatment Randomised, Double-Blind, Chronic-Dosing , Placebo-Controlled, • For the EU and Hybrid approaches, the Parallel-Group and Multi-centre primary endpoint will be the change from baseline in morning pre-dose trough Estimated time from FSFV to DBL is approximately 20 months. FEV1 over 24 weeks of treatment US, UK, Germany, Costa Rica, Hungary, Poland, Russia, South ▪ TDI score (co-primary endpoint for EU Korea, Taiwan, China, Japan and Hybrid) [Time Frame: Over 24 Weeks]

Phase IIb Moderate to severe COPD N = 40 Treatments (5-week Treatment Period) • Right Ventricular End Diastolic Volume • FPD: Q2 2016 (CV trial) • GFF MDI (PT003) 14.4/9.6 μg ex-actuator Index (RVEDVi) measured at 2-hours • LPCD: H2 2016 • Placebo MDI post-dose on Day 8 • Estimated top-line results: 2017 NCT02685293 Randomised, 2-period, Double-blind, 2-treatment, Chronic-dosing (7 Days), Crossover trial

Estimated time from FSFV to DB is approximately eight months, US

16 Lifecycle management Late-stage development Early development - IMED Brilinta/Brilique (ADP receptor antagonist) Early development - MedImmune Cardiovascular

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Patients with prior MI N = 21,000 • Arm 1: Brilinta/Brilique 90 mg BiD • Composite of CV death, non-fatal MI • FPD: Q4 2010 PEGASUS • Arm 2: Brilinta/Brilique 60 mg BiD and non-fatal stroke • LPCD: Q4 2014 • Arm 3: Placebo BiD • Completion date: Q4 2014 NCT01225562 on a background of ASA

Global trial – 31 countries

Phase III Patients with PAD N = 13,500 • Arm 1: Brilinta/Brilique 90 mg BiD • Composite of CV death, non-fatal MI • FPD: Q4 2012 EUCLID • Arm 2: Clopidogrel 75 mg QD and ischemic stroke • LPCD: H2 2016 monotherapy trial • Estimated top-line results: H2 2016 NCT01732822 Global trial – 28 countries

Phase III Patients with type-2 diabetes N = 19,000 • Arm 1: Brilinta/Brilique 60 mg BiD • Composite of CV death, non-fatal MI • FPD: Q1 2014 THEMIS and coronary artery disease • Arm 2: Placebo BiD and non-fatal stroke • LPCD: 2018 without a previous history of on a background of ASA if not contra indicated or not tolerated • Estimated top-line results: 2018 NCT01991795 MI or stroke Global trial – 42 countries

Phase III (BE) Japanese healthy volunteers N = 36 Single dose, Cross-Over • BE of ticagrelor Dispersible Tablet • FPD: Q2 2015 • Arm 1 Brilinta/Brilique OD tablet 90 mg + 150 mL of water vs ticagrelor IR tablet • LPCD: Q3 2015 NCT02436577 • Arm 2 Brilinta/Brilique OD tablet 90 mg without water • Completion date: Q3 2015 • Arm 3 Brilinta/Brilique IR tablet 90 mg) + 200 mL of water • Top-line results: Q4 2015

Local trial – one country

17 Lifecycle management Late-stage development Early development - IMED Brilinta/Brilique (ADP receptor antagonist) Early development - MedImmune Cardiovascular

Trial phase Patient population Number of patients Design Endpoints Status

Phase III (BE) Caucasian healthy volunteers N = 36 Single dose, Cross-Over • BA/BE of Brilinta/Brilique Dispersible • FPD: Q2 2015 • Arm 1 Brilinta/Brilique OD tablet 90 mg +200 ml of water Tablet vs Brilinta/Brilique IR tablet • LPCD: Q3 2015 NCT02400333 • Arm 2 Brilinta/Brilique OD tablet 90 mg without water • Completion date: Q3 2015 • Arm 3 Brilinta/Brilique OD tablet 90 mg (suspended in water) • Top-line results: Q4 2015 via nasogastric tube • Arm 4 Brilinta/Brilique IR tablet 90 mg + 200mL of water

Local trial – one country

Phase II Patients with sickle disease N = 90 • Arm 1: Brilinta/Brilique 10 mg BiD • Number of days with pain due to Sickle • FPD: Q3 2015 HESTIA2 • Arm 2: Brilinta/Brilique 45 mg BiD Cell Disease • LPCD: H2 2016 • Arm 3: Placebo BiD • Estimated completion date: H2 2016 NCT02482298 Global trial – eight countries

18 Lifecycle management Late-stage development Early development - IMED Onglyza (DPP-4 inhibitor) Early development - MedImmune Type-2 Diabetes

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Type-2 diabetes mellitus N = 444 • Arm 1: Onglyza 5 mg QD +insulin or Onglyza 5 mg QD+ insulin Primary: • FPD: Q3 2014 + Met: Placebo QD + insulin or Placebo • Change from baseline in HbA1C at • LPCD: Q1 2016 NCT02104804 • Arm 2: QD + insulin + Met 24 weeks • Estimated top-line results: Q2 2016

Trial in China Secondary: • Change from baseline at 24 weeks in 120-minute postprandial plasma glucose (PPG) in response to a meal tolerance

Phase III Type-2 diabetes mellitus N = 639 • Arm 1: Onglyza 5 mg + Met Primary: • FPD: Q1 2015 (500 mg with titration) • The change in HbA1c from baseline to • LPCD: H2 2016 NCT02273050 • Arm 2: Onglyza 5 mg + Placebo week 24 (prior to rescue) • Estimated top-line results: 2017 • Arm 3: Met (500 mg with titration) + Placebo Secondary: Trial in China • The proportion of subjects achieving a therapeutic glycaemic response at week 24 (prior to rescue) defined as HbA1c <7.0%

19 Lifecycle management Late-stage development Early development - IMED Farxiga/Forxiga (SGLT2 inhibitor) Early development - MedImmune Diabetes

Trial phase Patient population Number of patients Design Endpoints Status

Phase IV Japanese patients with type-2 N = 266 • Arm 1: Forxiga 5mg • Change from baseline in HbA1c at week • FPD: Q2 2014 diabetes with inadequate • Arm 2: Placebo 16 • LPCD: Q4 2015 NCT02157298 glycemic control on insulin • 1 year LT data • Top-line Results: Q1 2016 Japan trial • Estimated completion date: Q2 2016

Phase III/IV Type-2 diabetes N = 17,276 • Arm 1: Farxiga/Forxiga 10 mg QD + standard of care therapy • Time to first event included in the • FPD: Q2 2013 DECLARE mellitus with high QD composite endpoint of CV death, MI or • LPCD: 2019 risk for CV event • Arm 2: Placebo + standard of care therapy for type-2 Diabetes ischemic stroke • Estimated top-line results: 2019 NCT01730534 • Estimated completion date: 2019 Global trial – 33 countries

Phase III Asian subjects with type-2 N = 273 • Arm 1: Forxiga 10 mg QD for 24 weeks + background Insulin • Change from baseline in HbA1c at week • FPD: Q1 2014 diabetes who have inadequate • Arm 2: Placebo QD for 24 weeks + background Insulin 24 • LPCD: Q1 2016 NCT02096705 glycemic control on insulin • Estimated top-line results: Q2 2016 Asian trial – three countries • Estimated completion date: Q2 2016 Partnered: BMS

Phase III Patients with type-2 diabetes N = 302 • Arm 1: Farxiga/Forxiga 10 mg QD for 24 weeks • Change from baseline in HbA1c at Week • FPD: Q2 2015 DERIVE and moderate renal • Arm 2: Placebo 10 mg QD for 24 weeks 24 • LPCD: 2017 impairment • Estimated top-line results: 2017 NCT02413398 Global trial – 5 countries • Estimated completion date: 2017

Phase III Type-1 diabetes mellitus N = 768 • Arm 1: Farxiga/Forxiga 5 mg QD 52 weeks + insulin Primary: • FPD: Q4 2014 DEPICT 1 • Arm 2: Farxiga/Forxiga 10 mg QD 52 weeks + insulin • Adjusted Mean Change From Baseline • LPCD: 2017 NCT02268214 • Arm 3: Placebo QD 52 weeks + insulin in Haemoglobin A1C (HbA1c) at • Estimated top-line results: 2017 Week 24 Partnered: BMS Global trial – 17 countries

Phase III Type-1 diabetes mellitus N = 768 • Arm 1: Farxiga/Forxiga 5 mg QD 52 weeks + insulin Primary: • FPD: Q3 2015 DEPICT 2 • Arm 2: Farxiga/Forxiga 10 mg QD 52 weeks + insulin • Adjusted Mean Change From Baseline • LPCD: 2017 NCT02460978 • Arm 3: Placebo QD 52 weeks + insulin in Haemoglobin A1C (HbA1c) at • Estimated top-line results: 2018 Week 24 Partnered: BMS Global trial – 14 countries

20 Lifecycle management Late-stage development Early development - IMED Saxagliptin/dapagliflozin (DPP-4/SGLT2 inhibitors) Early development - MedImmune Diabetes

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Type-2 diabetes mellitus N = 420 • Arm 1: Saxagliptin 5 mg + dapagliflozin 10 mg + Met IR/XR Primary: • FPD: Q1 2015 • Arm 2: Sitagliptin 100 mg + Met IR/XR • Mean change from baseline in HbA1C at • LPCD: H2 2016 NCT02284893 week 24 • Estimated top-line results: H2 2016 Global trial – six countries Secondary: • The proportion of subjects achieving a therapeutic glycemic respons at week 24 defined as HbA1C<7% • Mean change in total body weight at week 24

Phase III Type-2 diabetes mellitus N = 440 • Arm 1: Saxagliptin 5 mg + dapagliflozin 10 mg + Met IR/XR Primary: • FPD: Q3 2015 • Arm 2: Glimeperide 1-6 mg + Met IR/XR • Mean change from baseline in HbA1c at • LPCD: 2017 NCT02419612 week 52 • Estimated top-line results: 2017 Global trial – 10 countries Secondary: • Mean change from baseline in total body weight at week 52 • The proportion of subjects achieving a therapeutic glycemic response at week 52 defined as HbA1c<7.0%

Phase III Type-2 diabetes mellitus N = 598 • Arm 1: Saxagliptin 5 mg + dapagliflozin 10 mg + Met IR/XR Primary: • FPD: Q4 2015 with or without SU • Mean change from baseline in HbA1C at • LPCD: 2017 NCT02551874 • Arm 2: Insulin glargine + Met IR/XR with or without SU week 24 • Estimated top-line results: 2017 Secondary: Global trial – 12 countries • Mean change in total body weight at week 24 • The proportion of subjects with confirmed hypoglycemia at week 24

Phase III Type-2 diabetes mellitus N = 900 • Arm 1: Saxagliptin 5 mg + dapagliflozin 5 mg + Met IR/XR Primary: • FPD: Q1 2016 • Arm 2: Dapagliflozin 5 mg + placebo + Met IR/XR • Mean change from baseline in HbA1C at • LPCD: 2017 NCT02681094 • Arm 3: Saxagliptin 5 mg + placebo + Met IR/XR week 24 • Estimated top-line results: 2017 Secondary: • The proportion of subjects achieving a Global trial – six countries therapeutic glycemic respons at week 24 defined as HbA1C<7% • Mean change in fasting plasma glucose at 24 weeks

21 Lifecycle management Late-stage development Early development - IMED Bydureon (GLP-1 receptor agonist) Early development - MedImmune Type-2 Diabetes

Trial phase Patient population Number of patients Design Endpoints Status

Phase IV Type-2 diabetes N = 14,000 • Arm 1: Bydureon once weekly 2mg SC • Time to first confirmed CV event in the • FPD: Q2 2010 EXSCEL • Arm 2: Placebo primary composite CV endpoint (CV • LPCD: 2017 death, non-fatal MI, non-fatal stroke) • Estimated completion: 2018 NCT01144338 On a background of standard of care medication, different degree of CV risk Partnered Global trial

Phase III Type-2 diabetes N = 375 • Arm 1: Bydureon BiD SC (autoinjector) • Change in HbA1c from baseline at • FPD: Q1 2013 DURATION-NEO 1 • Arm 2: Bydureon weekly suspension SC (autoinjector) 28 weeks • Completed: Q3 2014

NCT01652716 On a background of diet & exercise alone or with stable regimen of oral antidiabetics Partnered US only

Phase III Type-2 diabetes N = 360 • Arm 1: Sitagliptin • Change in HbA1c from baseline at • FPD: Q1 2013 DURATION-NEO 2 • Arm 2: Bydureon weekly suspension SC (autoinjector) 28 weeks • Completed : Q3 2014 • Arm 3: Placebo NCT01652729 On a background of diet & exercise alone or with stable regimen Partnered of oral antidiabetics

US only

Phase III Type-2 diabetes N = 440 • Arm 1: Bydureon once weekly 2 mg SC + Titrated Basal Insulin • Change in HbA1c from baseline at • FPD: Q3 2014 DURATION 7 • Arm 2: Placebo + Titrated Basal Insulin 28 weeks • LPCD: H2 2016 • Estimated completion: H2 2016 NCT02229383 Double-blind 1:1 randomisation Background therapy with or without Metformin

Global trial

22 Lifecycle management Late-stage development Early development - IMED Bydureon (GLP-1 receptor agonist) Early development - MedImmune Type-2 Diabetes

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Type-2 diabetes N = 660 • Arm 1: Bydureon once weekly 2 mg SC • Change in HbA1c from baseline at • FPD: Q3 2014 DURATION 8 • Arm 2: Dapagliflozin 10 mg 28 weeks • LPCD: 2017 • Arm 3: Bydureon once weekly 2 mg SC + dapagliflozin 10 mg • Estimated completion: NCT02229396 H2 2016 - 28-week data Double-blind 1:1:1 randomisation 2017 - 52-week data Background therapy with Metformin 1500 mg/day up to 2 months 2018 - 104-week data prior to screening

Global trial

23 Lifecycle management Late-stage development Early development - IMED Epanova (omega-3 carboxylic acids) Early development - MedImmune Hypertriglyceridaemia

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Japanese patients with N = 375 • Epanova 2 g and 4 g vs. Placebo (after meal) daily for 52 • Safety in Japanese patients • FPD: Q2 2015 Japanese Long-term Safety hypertriglyceridemia weeks • % change in triglycerides • LPCD: 2017 • Estimated top-line results: 2017 NCT02463071 Global trial – one country

Phase III Severe hyper-triglyceridaemia N = 162 • Arm 1: Epanova 2g QD • Change in serum triglycerides over • FPD: Q4 2013 EVOLVE II • Arm 2: Placebo (olive oil) 12 weeks • LPCD: Q4 2014 • Completed: Q4 2015 NCT02009865 Global trial – seven countries

Phase III Patients with hypertri- N = 13,000 • Arm 1: Epanova 4g QD + statin • Composite of MACE • FPD: Q4 2014 STRENGTH (CVOT) glyceridaemia and high CVD • Arm 2: Placebo (corn oil) + statin • Estimated top-line results: 2019 risk NCT02104817 Global trial – 22 countries

Phase II Overweight patients with N = 75 • Epanova 4 g vs. Placebo vs. Fenofibrate 200 mg daily for 12 • Reduction in liver fat content (%) at the • FPD: Q3 2015 EFFECT I hypertriglyceridemia weeks end of 12 weeks compared to placebo • LPCD: Q2 2016 • Reduction in liver fat content (%) at the • Estimated top-line results: H2 2016 NCT02354976 Global trial – one country end of 12 weeks compared to fenofibrate

Phase II Type-2 DiM N = 80 • Arm 1: Epanova 4g QD • Reduction in liver fat content (%) at the • FPD: Q1 2015 EFFECT II Liver fat >5.5% • Arm 2: Placebo (olive oil) end of 12 weeks • LPCD: Q4 2015 • Arm 3: Epanova 4gm + dapaglifozin 10 mg QD • Estimated top-line results: Q2 2016 NCT02279407 • Arm 4: Dapaglifozin 10 mg

Local trial – one country

Phase I Pancreatic Exocrine N = 66 • Arm 1: Epanova 4g single dose • Presence of Pancreatic Exocrine • FPD: Q1 2015 PRECISE Insufficiency (PEI) in patients • Arm 2: Omacor 4 g single dose Insufficiency (PEI), Pharmacokinetics of • LPCD: Q4 2015 with type-2 diabetes Epanova and Omacor following a single • Estimated top-line results: Q2 2016 NCT02370537 Global trial – six countries in Europe oral dose in patients with different degrees of PEI

24 Lifecycle management Late-stage development Early development - IMED Epanova (omega-3 carboxylic acids) Early development - MedImmune Hypertriglyceridaemia

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers N = 40 Part A • Arm 1: D1400147 4g • Rate and extent of absorption of omega- • FPD: Q1 2015 Microsphere bioavailability N = 42 Part B • Arm 2: D14000136 4g 3-carboxylic acids following single-dose • LPCD: Q3 2015 • Arm 3: D14000137 4g oral administration of test formulations A, • Completed: Q4 2015 NCT02359045 • Arm 4: Epanova 4g B and C and reference formulation (Epanova®) under fed and fasted Local trial – one country condition, by assessment of AUC, AUC(0-72) and Cmax

Phase I Healthy male volunteers N = 42 • Epanova 4 g X 3 separate occasions (fasting, before meal, and • Effect of food timing (fasting, before • FPD: Q1 2015 Japanese food interaction after meal) meal, and after meal) on • LPCD: Q2 2015 pharmacokinetics (AUC, Cmax, • Completed: Q4 2015 NCT02372344 Local trial – one country AUC0-72)

Phase I Healthy male Japanese and N = 18 • Arm 1: (Japanese): Epanova 2g vs. Placebo QD • PK of single and multiple doses in • FPD: Q3 2014 Caucasian subjects • Arm 2: (Japanese): Epanova 4g vs Placebo QD healthy male Japanese subjects • LPCD: Q4 2014 SAD/MAD • Arm 3: (Caucasian): Epanova 4g vs Placebo • Safety/tolerability profile • Completed: Q3 2015

NCT02209766 Local trial – one country

Phase I Patients with a history of N = 16 • Arm 1: Epanova 4g →Lovaza 4g QD • Plasma concentration vs. time curve • FPD: Q3 2014 pancreatitis • Arm 2: Lovaza 4g →Epanova 4 g QD (AUC0-τ) • LPCD: Q2 2015 NCT02189252 • Arm 3: Epanova 2g →Lovaza 4g QD [Time Frame: 0 to 24 hours • Top-line results: Q4 2015 • Arm 4: Lovaza 4g →Epanova 2g QD (AUC0-24)]

Global trial – two countries

25 Lifecycle management Late-stage development Early development - IMED Faslodex (oestrogen receptor antagonist) Early development - MedImmune Breast cancer - metastatic

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Postmenopausal women with N ~ 450 • Arm 1: Faslodex 500 mg monthly IM + an additional dose on • PFS • FPD: Q4 2012 FALCON HR+ locally advanced or d14 • OS is a secondary endpoint • LPCD: Q3 2014 metastatic breast cancer, who (+ oral placebo) • Estimated top-line results: Q2 2016 NCT01602380 have not previously been • Arm 2: Arimidex 1 mg treated with any hormonal (+ placebo injection) therapy (1L) Global trial – 21 countries

26 Lifecycle management Late-stage development Early development - IMED Lynparza (PARP inhibitor) Early development - MedImmune Ovarian cancer and other solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase III PSR BRCAm ovarian cancer N = 264 • Arm 1: Lynparza tablets 300 mg BiD as maintenance therapy • PFS • FPD: Q3 2013 SOLO-2 until progression • OS secondary endpoint • LPCD: Q4 2014 Partnered • Arm 2: placebo tablets BiD • Estimated top-line results: H2 2016

NCT01874353 Global trial

Phase III 1L maintenance BRCAm N = 344 • Arm 1: Lynparza tablets 300 mg BiD maintenance therapy for 2 • PFS • FPD: Q3 2013 SOLO-1 ovarian cancer years or until disease progression • OS secondary endpoint • LPCD: Q1 2015 Partnered • Arm 2: placebo • Estimated top-line results: 2017

NCT01844986 Global trial

Phase III PSR gBRCAm ovarian cancer N = 411 • Arm 1: Lynparza 300 mg BiD to progression • PFS • FPD: Q1 2015 SOLO-3 3L+ Line • Arm 2: Physician’s choice (single agent chemotherapy) • OS secondary endpoint • LPCD: 2017 • Estimated top-line results: 2018 NCT02282020 Global trial

Phase III 2L gastric cancer N = 525 • Arm 1: paclitaxel + Lynparza until progression • OS • FPD: Q3 2013 GOLD (all patients with a co-primary • Arm 2: paclitaxel + placebo • LPCD: Q4 2015 sub population) • Estimated top-line results: Q2 2016 NCT01924533 Lynparza dose 100mg BiD throughout paclitaxel dose cycle & 300 mg BiD post cycle

Asian trial

27 Lifecycle management Late-stage development Early development - IMED Lynparza (PARP inhibitor) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase III BRCAm metastatic breast N = 310 • Arm 1: Lynparza 300 mg BiD, continuous to progression • PFS • FPD: Q2 2014 OlympiAD cancer • Arm 2: Physician’s choice: • Secondary endpoint: OS • LPCD: Q4 2015 capecitabine 2500 mg/m2 x 14 q 21 • Estimated top-line results: H2 2016 NCT02000622 vinorelbine 30 mg/m2 d 1, 8 q 21 eribulin 1.4 mg/m2 d 1, 8 q 21 to progression

Global trial

Phase III BRCAm adjuvant breast N = 1,500 • Arm 1: Lynparza 300 mg BiD • Invasive Disease Free Survival (IDFS) • FPD: Q2 2014 OlympiA cancer 12 month duration • Secondary endpoint: Distant Disease • LPCD: 2018 Partnered • Arm 2: Placebo 12 month duration Free Survival and OS • Estimated top-line results: 2020

NCT02032823 Global trial partnership with BIG and NCI/NRG

Phase III Pancreas N = 145 • Arm 1: Lynparza tablets 300 mg twice daily as maintenance • Primary endpoint: PFS • FPD: Q1 2015 POLO gBRCA therapy until progression. • Secondary endpoint: OS • LPCD: 2017 • Arm 2: placebo tablets BiD • Estimated top-line results: 2018 NCT02184195 Global trial

Phase II Metastatic castration resistant N = 140 • Arm 1: Lynparza 300mg BiD + abiraterone • Radiologic PFS • FPD: Q3 2014 prostate CA • Arm 2: Placebo + abiraterone • LPCD: Q3 2015 NCT01972217 • Estimated top-line results: H2 2016 Global trial

28 Lifecycle management Late-stage development Early development - IMED Tagrisso (Highly selective, irreversible EGFR TKI) Early development - MedImmune Non-small cell lung cancer (NSCLC)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Advanced EGFRm NSCLC N = 410 • Arm 1: Tagrisso 80mg QD • PFS • FPD: Q3 2014 AURA3 TKI failure and primary • Arm 2: pemetrexed 500mg/m2 + carboplatin AUC5 or • OS is a secondary endpoint • Enrolment complete resistance mutation T790M pemetrexed 500mg/m2 + cisplatin 75mg/m2 (2:1 • PFS • Estimated primary completion: H2 2016 NCT02151981 randomisation • OS and QoL as secondary endpoints

Global trial Phase III Advanced EGFRm NSCLC 1L N = 530 • Arm 1: Tagrisso 80mg • PFS • FPD: Q1 2015 FLAURA • Arm 2: erlotinib 150mg or Iressa 250 mg (dealers choice); 1:1 • OS and QoL as secondary endpoints • Estimated completion: 2017 randomisation NCT02296125 Global trial Phase III Adjuvant EGFRm NSCLC N = 700 • Arm 1: Tagrisso 80mg QD following complete tumour • DFS • FPD: Q4 2015 ADAURA resection, with or without chemotherapy • DFS Rate, OS, OS Rate, QoL • Estimated completion: 2022 • Arm 2: Placebo NCT02511106 Global trial Phase III Advanced EGFRm NSCLC TKI N = 350 • Arm 1: Tagrisso (80mg QD) + MEDI4736 (10mg/kg q2w (IV) • PFS • FPD: Q3 2015 CAURAL failure and primary resistance infusion) • ORR, OS, QoL as secondary endpoints • Enrolment hold implemented in Q4 2015 mutation T790M • Arm 2: Tagrisso (80mg QD) Will not restart NCT02454933 Global trial Phase II Advanced EGFRm NSCLC TKI N = 175 • Tagrisso 80 mg QD • ORR • FPD: Q3 2015 AURA17 failure and primary resistance • PFS and OS secondary endpoints • Enrolment complete mutation T790M Asia Pacific Regional trial • Estimated primary completion: Q2 2016 NCT02442349

Phase II Advanced EGFRm NSCLC TKI N = 175 • Tagrisso 80 mg QD • ORR • FPD: Q2 2014 AURA2 failure and primary resistance • PFS and OS secondary endpoints • Enrolment complete (N = 210) mutation T790M Global trial NCT02094261

Phase I/II Advanced EGFRm NSCLC TKI N ~ 500 • Dose escalation trial • Safety and tolerability • FPD: Q1 2013 AURA failure + /- primary resistance • Ph II Extension cohort (T790M only) Tagrisso 80mg QD • ORR • Enrolment complete (N = 201 in mutation T790M • PFS and OS secondary endpoints extension portion) NCT01802632 Global trial

29 Lifecycle management Late-stage development Early development - IMED Tagrisso (Highly selective, irreversible EGFR TKI) Early development - MedImmune Non-small cell lung cancer (NSCLC)

Trial phase Patient population Number of patients Design Endpoints Status Phase Ib Advanced EGFRm NSCLC TKI N ~ 90 • Arm 1: Tagrisso + MEDI4736 • Safety, Tolerability, Pharmacokinetics • FPD: Q3 2014 TATTON failure • Arm 2: Tagrisso + AZD6094 and Preliminary Anti-tumour Activity • Dose escalation completed • Arm 3: Tagrisso + selumetinib • Dose expansions ongoing NCT02143466 • Enrolment to durvalumab combo arms Global trial will not restart Phase I EGFRm NSCLC, CNS disease N = 47 • MAD • Safety and tolerability • FPD: Q4 2014 BLOOM • Expansion in LM patients at RP2D with AZD3759 • Preliminary anti-tumour activity • Estimated primary completion: H2 2016 • Expansion in LM patients at 160mg with Tagrisso including NCT02228369 cohort with T790M NSCLC

Global trial – four countries

30 Lifecycle management Late-stage development Early development - IMED Nexium Early development - MedImmune Gastrointestinal

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Seriously ill patients with at N = 300 • Arm 1: Nexium 40 mg bid intermittent • Clinically significant upper GI bleeding • FPD: Q3 2014 least one major risk factor for iv infusions given for max.14 days • LPCD: Q1 2016 NCT02157376 stress ulcer related bleeding • Arm 2: Cimetidine 300 mg bolus iv infusion followed by • Estimated completion: Q2 2016 (Stress Ulcer Prophylaxis) continuous iv infusion 50mg/h for a maximum of 14 days

China-only trial

31 AstraZeneca

Late-stage development Lifecycle management Late-stage development Early development - IMED Brodalumab (IL-17R mAb) Early development - MedImmune Psoriasis

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Moderate to severe plaque N = 661 • Arm 1: 210 mg brodalumab SC • PASI at wk 12 • Completed - Partnered AMAGINE-1 psoriasis • Arm 2: 140 mg brodalumab SC • Static physician’s global assessment • Arm 3: Placebo SC (sPGA) at wk 12 NCT01708590

Phase III Moderate to severe plaque N = 1,800 • Arm 1: 210 mg brodalumab SC • PASI at wk 12 • Completed - Partnered AMAGINE-2 psoriasis • Arm 2: 140 mg brodalumab SC • Static physician’s global assessment • Arm 3: 45 or 90 mg ustekinumab SC (sPGA) at wk 12 NCT01708603 • Arm 4: Placebo SC

Phase III Moderate to severe plaque N = 1,881 • Arm 1: 210 mg brodalumab SC • PASI at wk 12 • Completed - Partnered AMAGINE-3 psoriasis • Arm 2: 140 mg brodalumab SC • Static physician’s global assessment • Arm 3: 45 or 90 mg ustekinumab SC (sPGA) at wk 12 NCT01708629 • Arm 4: Placebo SC

33 Lifecycle management Late-stage development Early development - IMED PT009 (ICS/LABA) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design (G = Glycopyrronium, F = Formoterol fumarate) Endpoints Status

Phase II Moderate to severe COPD N = 180 • BFF MDI 320/9.6 μg BiD • Forced expiratory volume in 1 second • FPD: Q3 2014 (BFF Dose-ranging) • BFF MDI 160/9.6 μg BiD area under the curve from 0 to 12 hours • LPCD: Q3 2014 • BFF MDI 80/9.6 μg BiD (FEV1 AUC0-12) • Top-line results: Q2 2015* NCT02196077 • BD MDI 320 μg BiD • FF MDI 9.6 μg BiD * Clinically completed Randomised, 4-period, 5-treatment incomplete-block and crossover

Estimated time from FSFV to DBL is approximately 7 months. US

34 Lifecycle management Late-stage development Early development - IMED PT010 (LABA/LAMA/ICS) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD) & Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Moderate to very severe N = 500 Treatments ( 52-week Treatment Period) Bone Mineral Density Sub-study Endpoint: • FSD: Q3 2015 (Long-term BMD and Ocular COPD • BGF MDI 320/14.4/9.6 µg • Change from baseline in BMD of the • LPCD: H2 2016 Safety) • GFF MDI 14.4/9.6 µg lumbar spine measured using DXA • Estimated top-line results: 2017 • BFF MDI 320/9.6 µg scans of L1-L4 at Week 52 NCT02536508 • Symbicort TBH 400/12 µg Ocular Sub-study Safety Endpoint: Randomised, double-blind, chronic-dosing, multi-centre • Change from baseline in LOCS III at Week 52 Estimated time from FSFV to DBL is approximately 21 months, Country – US

Phase III Moderate to very severe N = 8,000 Treatments ( 1-year Treatment Period) • Rate of moderate or severe COPD • FPD: Q3 2015 (Exacerbation trial) COPD (possible increase by • BGF MDI 320/14.4/9.6 µg BID exacerbations • LPCD: 2017 ETHOS 4,000 after blinded • BGF MDI 160/14.4/9.6 µg BID • Time to first moderate or severe COPD • Estimated top-line results: 2018 sample size re- • BFF MDI 320/9.6 µg BID exacerbation NCT02465567 assessment) • GFF MDL 14.4/9.6 µg BID Randomised, double-blind, multi-centre and parallel-group

Estimated time from FSFV to DBL is approximately three years. Multi-country

Phase III Moderate to very severe N = 1,800 Treatments ( 24-week Treatment Period) Co-Primary Endpoints (EU): • FPD: Q3 2015 (Lung function trial) COPD • BGF MDI 320/14.4/9.6 µg • FEV1 area under curve from 0 to 4 • LPCD: H2 2016 KRONOS • GFF MDI 14.4/9.6 µg hours (AUC0-4) over 24 weeks (BGF • Estimated top-line results: 2017 • BFF MDI 320/9.6 µg MDI vs BFF MDI and BGF MDI vs NCT02497001 • Symbicort TBH 400/12 µg Symbicort TBH) Randomised, double-blind, parallel-group, and chronic dosing and • Change from baseline in morning pre- multi-centre dose trough FEV1 over 24 weeks (BGF MDI vs GFF MDI) Estimated time from FSFV to DBL is approximately two years. • Transition dyspnea index (TDI) focal Multi-country score over 24 weeks (BGF MDI vs BFF MDI and BGF MDI vs GFF MDI) Primary Endpoint (Japan): • Change from baseline in morning pre- dose trough FEV1 over 24 weeks (BGF MDI vs BFF MDI, BGF MDI vs GFF MDI) Primary Endpoint (US): • FEV1 area under curve from 0 to 4 hours (AUC0-4) at Week 24 (BGF MDI vs BFF MDI • Change from baseline in morning pre- dose trough FEV1 at Week 24 (MDI vs GFF MDI)

35 Lifecycle management Late-stage development Early development - IMED PT010 (LABA/LAMA/ICS) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD) & Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Adult mild to moderate N = 150 • Arm 1: BD MDI 320 μg BiD • Change from baseline in morning pre- • FPD: Q2 2014 (BD Dose-ranging in persistent asthma • Arm 2: BD MDI 160 μg BiD dose trough forced expiratory volume in • LPCD: Q1 2015 Asthma) • Arm 3: BD MDI 80 μg BiD one second (FEV1) • Top-line results: Q3 2015 • Arm 4: BD MDI 40 μg BiD • Mean evening pre-dose peak flow rate NCT02105012 • Arm 5: Placebo MDI BiD (PEFR) * Clinically completed Randomised, 4-period, 5-treatment incomplete-block and • Mean number of puffs of rescue Ventolin crossover hydrofluoroalkane (HFA) • Asthma Control Questionnaire score Four week estimated time from FSFV to DBL is approximately 18 months. US

Phase II Intermittent asthma/mild to N = 200 Treatment (18-week Treatment Period) • Peak change from baseline in FEV1 • FPD: Q2 2015 moderate persistent asthma • GP MDI 28.8 μg BiD within 3 hours post-dosing on • LPCD: Q4 2015 NCT02433834 • GP MDI 14.4 μg BiD Day 15 • Estimated top-line results: Q2 2016 • GP MDI 7.2 µ BID • GP MDI 3.6 µ BID • Severent® Diskus® 50µ BID • Placebo MDI

Randomised, double-blind, chronic-dosing, placebo controlled, incomplete block, cross over, multi-centre, dose-ranging trial

Estimated time from FSFV to DBL is approximately 11 months. US

36 Lifecycle management Late-stage development Early development - IMED PT010 (LABA/LAMA/ICS) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD) & Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers N = 72 • Arm 1: BGF MDI 320/14.4/9.6 μg • Overall safety • FPD: Q3 2014 (BGF PK trial) • Arm 2: BFF MDI (320/9.6 µg) • PK parameters AUC0-12 and Cmax • LPCD: Q3 2014 • Arm 3: Symbicort Turbuhaler 400/12 μg • Top-line results: Q4 2014* NCT02189304 Randomised, double-blind, single-dose, 3-period, 3-treatment and crossover * Clinically completed

Estimated time from FSFV to DBL is approximately three months. US

Phase I Japanese healthy volunteers N = 20 Treatment (2-week Treatment Period) • Overall safety • FPD: Q3 2014 (BGF PK in Japanese • Arm 1: BGF MDI 320/14.4/9.6 μg • PK parameters AUC0-12 and Cmax • LPCD: Q3 2014 Subjects) • Arm 2: BGF MDI 160/14.4/9.6 μg • Top-line results: Q4 2014* • Arm 3: Placebo MDI NCT02197975 Randomised, double-blind, placebo-controlled, * Clinically completed 2-period, ascending-dose and crossover

Estimated time from FSFV to DBL is approximately eight weeks. Japan

Phase I Japanese healthy volunteers N = 24 Treatment (4-day Treatment Period) • Overall safety • FPD: Q3 2014 (GFF PK in Japanese • Arm 1: GFF MDI 14.4/9.6 μg • PK parameters AUC0-12 and Cmax • LPCD: Q3 2014 Subjects ) • Arm 2: GFF MDI 28.8/9.6 μg • Top-line results: Q4 2014* • Arm 2: GP MDI 14.4 μg NCT02196714 • Arm 2: GP MDI 28.8 μg * Clinically completed Randomised, double-blind, single-dose, 4-Period, 4-treatment and crossover

Estimated time from FSFV to DBL is approximately 13 weeks. Japan

37 Lifecycle management Late-stage development Early development - IMED Benralizumab (IL-5R mAb) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Severe asthma, inadequately N = 1,026 HD + ~200 • Arm 1: 30 mg Q8w SC • Annual asthma exacerbation rate • FPD: Q4 2013 CALIMA controlled despite background MD • Arm 2: 30 mg Q4w SC • Assess pulmonary function, asthma • Estimated completion: Q2 2016 controller medication, MD & • Arm 3: Placebo SC symptoms, other asthma control metrics, NCT01914757 HD ICS + LABA ± chronic ER/ED hospitalisation visits, PK, and IM OCS 56-week trial Age 12 – 75yrs Global trial – 11 countries

Phase III Severe asthma, inadequately N = 1,134 • Arm 1: 30 mg Q8w SC • Annual asthma exacerbation rate • FPD: Q4 2013 SIROCCO controlled despite background • Arm 2: 30 mg Q4w SC • Assess pulmonary function, asthma • Estimated completion: Q2 2016 controller medication HD ICS • Arm 3: Placebo SC symptoms, other asthma control metrics, NCT01928771 + LABA ± chronic OCS ER/ED hospitalisation visits, PK, and IM Age 12 – 75 yrs 48-week trial Global trial – 17 countries

Phase III Severe asthma, inadequately N = 210 • Arm 1: 30 mg Q8w SC • Reduction of oral corticosteroid dose • FPD: Q3 2014 ZONDA controlled on HD ICS plus • Arm 2: 30 mg Q4w SC • Estimated completion: H2 2016 long-acting β2 agonist and • Arm 3: Placebo SC NCT02075255 chronic oral corticosteroid therapy 46-week trial Age 18 – 75 yrs Global trial – 12 countries

38 Lifecycle management Late-stage development Early development - IMED Benralizumab (IL-5R mAb) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Asthmatic with FEV1 (50-90% N = 200 • Arm 1: 30 mg Q4W SC • Pulmonary function (FEV1) • FPD: Q1 2015 BISE predicted) on low to medium • Arm 3: Placebo SC • Completion: Q1 2016 dose inhaled corticosteroid NCT02322775 Age 18 – 75 yrs 12-week trial Global trial – six countries

Phase III Severe asthma, inadequately N = 2,550 • Arm 1: 30 mg Q4W SC • Safety and tolerability • FPD: Q4 2014 BORA controlled despite background • Arm 2: 30 mg Q8W SC* • Estimated completion: 2018 controller medication, MD & NCT02258542 HD ICS + LABA ± chronic * Placebo administered at select interim visits to OCS maintain blind between treatment arms Age 12 – 75yrs 56-week (adults) 108-week (adolescents) Global trial

Phase III Severe asthma, inadequately N = 120 • Arm 1: 30 mg Q4W SC • Functionality, Reliability, and • FPD: Q2 2015 GREGALE controlled despite background Performance of a Pre-filled Syringe With • Estimated completion: H2 2016 controller medication, MD & 28-week (adults) Benralizumab Administered at Home NCT02417961 HD ICS + LABA ± chronic Global trial – two countries OCS Age 18 – 75yrs

39 Lifecycle management Late-stage development Early development - IMED Benralizumab (IL-5R mAb) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Moderate to very severe N = 2,168 • Arm 1: 10 mg Q8W SC • Rate of COPD exacerbation • FPD: Q3 2014 TERRANOVA COPD with exacerbation • Arm 2: 30 mg Q4W SC • Estimated completion: 2018 history • Arm 3: 100 mg Q8W SC NCT02155660 • Arm 4: Placebo SC

48-week trial Global trial – 23 countries

Phase III Moderate to very severe N = 1,626 • Arm 1: 30 mg Q4W SC • Rate of COPD exacerbation • FPD: Q3 2014 GALATHEA COPD with exacerbation • Arm 2: 100 mg Q8W SC • Estimated completion: 2018 history • Arm 3: Placebo SC NCT02138916 48-week trial Global trial – 17 countries

40 Lifecycle management Late-stage development Early development - IMED Tralokinumab (IL-13 mAb) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Adults with uncontrolled N = 1,140 Cohort 1: Primary: • FPD: Q3 2014 STRATOS 1 severe asthma • Arm 1: Tralokinumab dose regimen 1, SC • Asthma exacerbation rate reduction • LPCD: Q1 2016 • Arm 2: Placebo SC Key Secondary: • Estimated completion date: 2017 NCT02161757 Cohort 2 : • Effect of tralokinumab on measures of • Estimated top-line results: 2017 • Arm 1: Tralokinumab dose regimen 2, SC pulmonary function (FEV1), asthma • Arm 2: Placebo SC symptoms (Asthma Daily Diary), asthma control (ACQ-6) and asthma related QoL 2:1 randomisation in both cohorts (AQLQ (S) +12)

Global trial – 15 countries

Phase III Adults with uncontrolled N = 770 • Arm 1: Tralokinumab SC Primary: • FPD: Q1 2015 STRATOS 2 severe asthma • Arm 2: Placebo SC • Asthma exacerbation rate reduction • LPCD: H2 2016 Key Secondary: • Estimated completion date: 2017 NCT02194699 1:1 randomisation • Effect of tralokinumab on measures of • Estimated top-line results: 2017 pulmonary function (FEV1), asthma Global trial – 13 countries including Japan symptoms (Asthma Daily Diary), asthma control (ACQ-6) and asthma related QoL (AQLQ (S) +12)

Phase III Adults with oral corticosteroid N = 120 • Arm 1: Tralokinumab SC Primary: • FPD: Q1 2015 TROPOS dependent asthma • Arm 2: Placebo SC • % Change in OCS dose • LPCD: H2 2016 Key Secondary: • Estimated completion date: 2017 NCT02281357 1:1 randomisation • Proportion of subjects achieving final • Estimated top-line results: 2017 daily OCS dose ≤5 mg Global trial – six countries • Proportion of subjects achieving ≥50% reduction in OCS dose

Phase II Adults with uncontrolled N = 80 • Arm 1: Tralokinumab SC Primary: • FPD: Q3 2015 MESOS asthma • Arm 2: Placebo SC • Change in number of airway • LPCD: 2017 submucosal eosinophils • Estimated completion date: 2017 NCT02449473 1:1 randomisation Secondary: • Estimated top-line results: 2017 • Change in blood eosinophils levels Global trial – three countries • Change in eosinophil cationic protein as a measure of activated eosinophils in blood and sputum

41 Lifecycle management Late-stage development Early development - IMED Tralokinumab (IL-13 mAb) Early development - MedImmune Atopic dermatitis

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Adults with atopic dermatitis N = 306 • Arm 1: Tralokinumab dose 45mg SC • Change from baseline in SCORAD at • FPD: Q1 2015 • Arm 2: Tralokinumab dose 150mg SC week 12 • LPCD: Q4 2015 NCT02347176 • Arm 3: Tralokinumab dose 300mg SC • Completion date: Q1 2016 • Arm 4: Placebo SC Key Secondary Endpoints: • Top-line results: Q1 2016 • Percentage of subjects achieving IGA of Global trial – six countries 0 or 1 • Change from baseline in EASI • Percentage of subjects achieving EASI50 and SCORAD50 • Change from baseline in pruritis • Safety and tolerability • Tralokinumab serum concentration

42 Lifecycle management Late-stage development Early development - IMED Anifrolumab (type I IFN receptor mAb) Early development - MedImmune Systemic Lupus Erythematosus (SLE)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Moderate to severe SLE N = 450 • Arm 1: 300 mg IV MEDI-546 Q4W for 48 weeks Response in SLE responder index at week • FPD: Q3 2015 TULIP SLE 1 • Arm 2: 150 mg IV MEDI-546 Q4W for 48 weeks 52 • LPCD: 2018 NCT02446912 • Arm 3: Placebo IV Q4W for 48 weeks • Estimated top-line results: 2018

Phase III Moderate to severe SLE N = 360 • Arm 1: 300 mg IV MEDI-546 Q4W for 48 weeks Response in SLE responder index at week • FPD: Q3 2015 TULIP SLE 2 • Arm 2: 150 mg IV MEDI-546 Q4W for 48 weeks 52 • LPCD: 2018 NCT02446899 • Estimated top-line results: 2018

Phase ll Moderate to severe SLE N = 307 (final) • Arm 1: 300 mg IV MEDI-546 Q4W for 48 weeks Response in SLE responder index at 6 • FPD: Q1 2012 patients • Arm 2: 1000 mg IV MEDI-546 Q4W for 48 weeks months • Top-line results: Q3 2014 NCT01438489 • Arm 3: Placebo IV Q4W for 48 weeks

Phase II Moderate to severe SLE N = 218 • Arm 1: MEDI-546, IV Q4W for 104 weeks Open-label extension to evaluate long-term • FPD: Q1 2013 patients safety and tolerability • Estimated top-line results: 2017 NCT01753193

Phase II Japanese SLE patients N = 17 Open-label, dose escalation trial: Safety, tolerability, PK/PD • Top-line results: Q1 2015 • Arm 1: 100mg IV Q4W for 48 weeks then 300mg IV Q4W for NCT01559090 104 weeks • Arm 2: 300mg IV Q4W for 48 weeks then 300mg IV Q4W for 104 weeks • Arm 3: 1000mg IV Q4W for 48 weeks then1000mg IV Q4W for 104 weeks

Phase I Healthy volunteers N= 30 • Arm 1: 300mg SC single dose Safety, tolerability, PK/PD • FPD: Q4 2015 • Arm 2: 300mg IV single dose • LPCD: H1 2016 NCT02601625 • Arm 3: 600 mg SC single dose • Estimated top-line results: H2 2016

43 Lifecycle management Late-stage development Early development - IMED Anifrolumab (type I IFN receptor mAb) Early development - MedImmune Lupus Nephritis (LN)

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Active Proliferative LN (TULIP- N = 150 • Arm 1: 900 mg IV Q4W for 12 weeks then 300 mg IV MEDI- Response in proteinuria at week 52 • FPD: Q4 2015 LN1) 546 Q4W for 36 weeks • LPCD: 2018 NCT02547922 • Arm 2: 300 mg IV MEDI-546 Q4W for 48 weeks • Estimated top-line results: 2018 • Arm 3: Placebo IV Q4W for 48 weeks

44 Lifecycle management Late-stage development Early development - IMED Acalabrutinib (ACP-196) Early development - MedImmune Rheumatoid Arthritis

Trial phase Patient population Number of patients Design Endpoint(s) Status

Phase II Rheumatoid Arthritis N=70 • Arm A: Acalabrutinib + methotrexate Disease Activity Score 28-CRP at week 4 FPD: Q2 2015 ACE-RA-001 • Arm B: Methotrexate Estimated Completion: 2017 NCT02387762

45 Lifecycle management Late-stage development Early development - IMED Roxadustat (HIF-PHI) Early development - MedImmune Chronic Kidney Disease (CKD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III ANDES Anaemia in CKD patients not N = 600 • Arm 1: Roxadustat Haemoglobin response • FPD: Q4 2012 receiving • Arm 2: Placebo • Estimated completion: 2017 NCT01750190 dialysis Sponsored by FibroGen Global trial – 15 countries

Phase III ALPS N = 600 • Arm 1: Roxadustat Haemoglobin response • FPD: Q2 2013 • Arm 2: Placebo • Estimated completion: Q2 2016 NCT01887600 Sponsored by Astellas Global trial – 16 countries

Phase III DOLOMITES N = 570 • Arm 1: Roxadustat Haemoglobin response • FPD: Q1 2014 • Arm 2: Darbepoetin alfa • Estimated completion: 2017 NCT02021318 Sponsored by Astellas Global trial –17 countries

Phase III OLYMPUS N = 2,600 • Arm 1: Roxadustat MACE • FPD: Q3 2014 • Arm 2: Placebo • Estimated completion: 2017 NCT02174627 Sponsored by AstraZeneca Global trial – 24 countries

Phase III ROCKIES Anaemia in CKD in patients N = 1,425 • Arm 1: Roxadustat MACE • FPD: Q3 2014 receiving dialysis • Arm 2: Epoetin alfa • Estimated completion: 2017 NCT02174731 Sponsored by AstraZeneca Global trial – 18 countries

Phase III SIERRAS N = 600 • Arm 1: Roxadustat Haemoglobin response • FPD: Q4 2014 • Arm 2: Epoetin alfa • Estimated completion: 2017 NCT02273726 Sponsored by FibroGen Global trial – one country

Phase III PYRENEES N = 750 • Arm 1: Roxadustat Haemoglobin response • FPD: Q4 2014 • Arm 2: Erythropoiesis Stimulating Agent • Estimated completion: 2017 NCT02278341 • Arm 3: Darbepoetin alfa Sponsored by Astellas

Global trial – 19 countries

Phase III HIMALAYAS Anaemia in newly initiated N = 1000 • Arm 1: Roxadustat Haemoglobin response • FPD: Q4 2013 dialysis patients • Arm 2: Epoetin alfa • Estimated completion: 2017 NCT02052310 Sponsored by FibroGen Global trial – 18 countries

46 Lifecycle management Late-stage development Early development - IMED Cediranib (VEGF receptor inhibitor) Early development - MedImmune Ovarian cancer

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Patients with platinum- N = 486 • Arm 1: Placebo • PFS • FPD: Q2 2007 ICON 6 sensitive relapsed ovarian • Arm 2: concurrent cediranib • Completed cancer • Arm 3: concurrent and maintenance cediranib NCT00532194

47 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune Non-small cell lung cancer (NSCLC)

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Adjuvant NSCLC patients N = 1,100 • Arm 1: MEDI4736 mg/kg IV Q4W x 12 mos • DFS • FPD: Q1 2015 ADJUVANT IB (≥4cm) – IIIA resected • Arm 2: Placebo • OS • Estimated completion: 2020 NSCLC NCT02273375 (incl. EGFR/ALK pos) Global trial

Partnered with NCIC CTG

Phase III Unresectable Stage III NSCLC N = 702 • Arm 1: MEDI4736 IV Q2W • PFS • FPD: Q2 2014 PACIFIC patients following platinum- • Arm 2: placebo • OS • LPCD: Q2 2016 based concurrent chemo- • Estimated completion: 2017 NCT02125461 radiation therapy Global trial

Phase II/III Lung Master Stage IV squamous NSCLC N = 140 ; 100 Umbrella trial with 5 arms based on biomarker expression • FPD: Q2 2014 Protocol patients Durvalumab • Substudy A: MEDI4736 (non-match for other biomarker driven Arm 1 • Estimated completion: 2022 treated (4736 substudies) IVQ2W single arm MEDI4736 PhII only • ORR, PDL1 + NCT02154490 Biomarker-targeted substudy only); • Substudy B: PI3K Inhibitor vs. docetaxel 2L therapy • Substudy C: CDK4/6 inhibitor vs. docetaxel Partnered with NCI, FNIH, • Substudy D: AZD4547 (FGFR inhibitor) vs. docetaxel and SWOG • Substudy E: C-MET/HGFR Inhibitor + erlotinib vs. Erlotinib (Substudy is closed)

Phase II Stage IIIB-IV NSCLC patients N = 293 • Arm 1: MEDI4736 IV Q2W (EFGR/ALK WT) • Objective Response Rate • FPD: Q1 2014 ATLANTIC • Arm 2: MEDI4736 IV Q2W (EFGR/ALK M+) • Secondary endpoints include duration of • LPCD: Q2 2015 PD-L1+ve patients • Arm 3: MEDI4736 IV Q2W (EFGR/ALK WT) (90% PD-L1 - response, PFS and OS • First data: Q4 2015 NCT02087423 3L expression) • Estimated completion: H2 2016

Global trial – 18 countries

Phase I/II Sequencing Study Stage IIIB-IV NSCLC patients N = 72 • Arm 1: Iressa initially then switch to MEDI4736 IVQ2W • Complete Response Rate • FPD: Q3 2014 • Arm 2: AZD9291 then switch to MEDI4736 • LPCD: Q2 2016 NCT02179671 • Arm 3: selumetinib + docetaxel then switch to MEDI4736 • ORR, Disease Control Rate • Estimated completion: H2 2016 • Arm 4: tremelimumab then switch to MEDI4736

48 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune Squamous Cell Carcinoma of the Head & Neck (SCCHN) and other solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase II SCCHN N = 112 • Single-arm: MEDI4736 IV Q2W • ORR • FPD: Q1 2015 HAWK 2L PD-L1 positive • LPCD: Q2 2016 • Estimated completion: H2 2016 NCT02207530

Phase I Solid tumours N = 108 • Dose Escalation: N=36, 3 cohorts receiving Treatment A • Safety and Tolerability • FPD: Q4 2014 (mogamulizumab + MEDI4736) and 3 cohorts receiving • MTD • LPCD: Q4 2015 NCT02301130 Treatment B (mogamulizumab + treme), in parallel • ORR, DoR, DCR, PFS, OS • Estimated completion: H2 2016

Partnered with KHK • Dose Expansion: N=72, Multiple solid tumour types (NSCLC, Head and Neck, Pancreatic), Treatment A or B (12 subjects per treatment per disease type, in parallel)

Phase I Solid tumours N = 176 • Dose Escalation: 3 cohorts at Q2W and 1 cohort at Q3W • Safety • FPD: Q3 2013 (all-comers) • Dose Expansion: Biliary Tract Cancer, Esophageal Cancer and • Optimal biologic dose • LPCD: Q4 2014 NCT01938612 SCCNH, Q2, and Q4 schedule • Estimated completion: 2017 • Dose Expansion of combination: Biliary Tract Cancer and Esophageal Cancer, MEDI4736 Q4W 20 mg/kg + tremelimumab Q4W 1 mg/kg

Trial conducted in Japan

49 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune + tremelimumab (CTLA-4 mAb) Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Stage IIIB-IV 3L NSCLC N = 480 • Arm 1: MEDI4736 + tremelimumab (PD-L1 –ve patients) • PFS Combination therapy ARCTIC patients who have not be • Arm 2: Standard of Care • OS • FPD: Q2 2015 tested positive for EGFR/ALK • Arm 3: tremelimumab (PD-L1 –ve patients) • Safety • LPCD: Q2 2016 NCT02352948 mutation • Arm 4: MEDI4736 (PD-L1 –ve patients) • Estimated completion: 2017 (PFS, OS)

Phase III NSCLC 1L N = 780 • Arm 1: MEDI4736 • PFS • FPD: Q3 2015 MYSTIC • Arm 2: MEDI4736 + tremelimumab • OS • LPCD: Q2 2016 • Arm 3: Standard of care • Safety • Estimated completion: 2017 NCT02453282

Phase III NSCLC 1L N = 800 • Arm 1: MEDI4736 + tremelimumab • OS • FPD: Q4 2015 NEPTUNE • Arm 2: Standard of care • Safety • LPCD: 2017 • Estimated completion: 2018

Phase III SCCHN 2L N = 720 • Arm 1: MEDI4736 + tremelimumab • OS • FPD: Q4 2015 EAGLE • Arm 2: MEDI4736 • PFS • LPCD: 2017 • Arm 3: Standard of care • Safety • Estimated completion: 2018

Phase III SCCHN 1L N = 628 • Arm 1: MEDI4736 • PFS • FPD: Q4 2015 KESTREL • Arm 2: MEDI4736 + tremelimumab • OS • LPCD: 2017 • Arm 3: Standard of care • Safety • Estimated completion: 2018 NCT02551159

Phase III Bladder 1L cis eligible and N = 525 • Arm 1: MEDI4736 + tremelimumab • PFS • FPD: Q4 2015 DANUBE ineligible • Arm 2: MEDI4736 • OS • LPCD: 2017 • Arm 3: Standard of care • Safety • Estimated completion: 2018 NCT02516241

50 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune + tremelimumab (CTLA-4 mAb) Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase II SCCHN N = 240 • Arm 1: MEDI4736 • ORR • FPD: Q2 2015 CONDOR 2L PD-L1 negative • Arm 2: Tremelimumab • Safety • LPCD: Q2 2016 • Arm 3: Tremelimumab + MEDI4736 • Estimated completion: 2017 NCT02319044

Phase II Metastatic Pancreatic Ductal N = 130 • Arm 1: MEDI4736 + tremelimumab • Safety • FPD: Q4 2015 ALPS Carcinoma 2L • Arm 2: MEDI4736 • Objective Response rate • LPCD: 2017 • Pharmacokinetics • Estimated completion: 2018 NCT02558894

Phase II Urothelial Bladder Cancer N=76 • Arm 1 Tremelimumab in Urothelial Bladder Cancer Safety • FPD: Q1 2016 Triple-negative Breast Cancer • Arm 2 TremelimumabTriple-negative Breast Cancer Objective Response rate • Estimated completion: 2018 Pancreatic Ductal- • Arm 3 Tremelimumab Pancreatic Ductal-Adneocarcinoma Duration of Response NCT02527434 Adneocarcinoma

Phase I combination in Solid tumours (treme Phase I) N = 22 • Tremelimumab + MEDI4736 • Safety • FPD: Q2 2014 advanced solid tumours in • Dose Escalation trial • Optimal biologic dose • LPCD: Q2 2015 Japanese patients • Tremelimumab Q4W/Q12W 3-10mg/kg • Estimated completion: H2 2016 • Tremelimumab Q4W/Q12W X mg/kg + MEDI4736 Q4W X NCT02141347 mg/kg

Phase 1 Combination in Solid tumours N = 80 • Arm 1 Ovarian cancer and SCCHN: Durvalumab + • Safety • FPD: Q1 2016 Advanced Solid Tumours tremelimumab + paclitaxel + carboplatin IV infusion • LPCD: 2018 • Arm 2 SCLC. Durvalumab + tremelimumab + carboplatin + • Estimated Completion: 2018 NCT02658214 etoposide • Arm 3 TNBC: Durvalumab + tremelimumab + gemcitabine + carboplatin • Arm 4 TNBC: Durvalumab + tremelimumab + nab-paclitaxel (paclitaxel-albumin) + carboplatin • Arm 5 Gastric/gastro-esophageal junction (GEJ): Durvalumab + tremelimumab + oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)

51 Lifecycle management Late-stage development Early development - IMED Selumetinib (AZD6244) (MEK-inhibitor) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase III 2L KRASm positive NSCLC N = 500 • Arm 1: Selumetinib 75mg BiD + docetaxel 75 mg/m2 IV on day • PFS • FPD: Q4 2013 SELECT-1 1 of each 21 day cycle • OS is a secondary endpoint • LPCD: Q1 2016 • Arm 2: Placebo BiD + docetaxel 75 mg/m2 IV on day 1 of each • Estimated top-line results: H2 2016 NCT01933932 21 day cycle

Global trial – 26 countries

Phase III Differentiated thyroid cancer N = 304 • Arm 1: Selumetinib 75mg BiD 5 weeks duration + RAI 100mCia • Complete remission (CR) rate at 18 • FPD: Q3 2013 ASTRA • Arm 2: Placebo BiD 5 weeks duration + RAI 100mCia months post-RAI • LPCD: Q1 2016 • Clinical remission rate at 18 m post RAI • Estimated top-line results: 2017 NCT01843062 Global trial – eight countries (per SoC)

a 131 Single dose of 100mCi I administered following 4 weeks of selumetinib (or placebo).

Phase II 2L KRASm negative NSCLC N = 225 • Arm 1: Selumetinib 75mg BiD + docetaxel 75 mg/m2 IV on day • PFS • FPD: Q1 2013 SELECT-2 1 of each 21 day cycle • OS is a secondary endpoint • LPCD: Q4 2015 • Arm 2: Selumetinib 75mg BiD + docetaxel 60 mg/m2 IV on day • Estimated top-line results: Q2 2016 NCT01750281 1 of each 21 day cycle • Arm 3: Placebo BiD + docetaxel 75 mg/m2 IV on day 1 of each 21 day cycle

Global trial – seven countries

Phase II Pediatric Neurofibromatosis N = minimum of 50 • Single Arm: Selumetinib 25mg/m2 BID with 2 strata: • Complete partial and complete response • FPD: Q3 2015 type 1 symptomatic pts • Stratum 1: PN related morbidity present at enrolment rate measured by volumetric MRI; • LPCD: H2 2016 NCT01362803 (current Ph I) • Stratum 2: No PN related morbidity present at enrolment • Duration of response and functional • Estimated top-line results: 2017 – partnered (NCI) outcomes/QoL

Advanced solid tumours Phase I N = 40 • Dose escalation trial: Starting dose Selumetinib 50mg bd 1 • Safety and tolerability • FPD: Q4 2015 week on/1 week off - MEDI4736 20mg/kg Q4 – after 7 days of • PK of Selumetinib and MEDI4736 and • LPCD: H2 2016 NCT02586987 selumetinib dosing. preliminary anti-tumour activity • Estimated top-line results: 2017 • Note: No escalation in MEDI4736 dose; Selumetinib escalation with 25 mg bd increment / dose cohort

52 Lifecycle management Late-stage development Early development - IMED Acalabrutinib (ACP-196) Early development - MedImmune Haematological malignancies

Trial phase Patient population Number of patients Design Endpoint(s) Status

Phase III Relapsed/refractory chronic N = 500 • Arm A: Acalabrutinib PFS • FPD: Q4 2015 ACE-CL-006 lymphocytic leukaemia (CLL), • Arm B: Ibrutinib Secondary endpoints: comparison of ELEVATE-RR high risk incidence of infections, RTs and atrial fibrillation, OS • Estimated Completion: 2018 NCT02477696

Phase III Previously untreated CLL N = 510 • Arm A: Chlorambucil + obinutuzumab PFS (Arm A vs Arm B) • FPD: Q3 2015 ACE-CL-007 • Arm B: Acalabrutinib + obinutuzumab Secondary endpoints: IRC assessed ORR, ELEVATE-TN • Arm C: Acalabrutinib TTNT, OS (arm A vs Arm B vs. Arm C) • Estimated Completion: 2019 NCT02475681

Phase II Relapsed/refractory CLL, N = 80 Acalabrutinib monotherapy ORR at 36 cycles • FPD: Q1 2016 ACE-CL-208 intolerant to ibrutinib • Estimated Completion: 2020 NCT02717611

Phase II Relapsed/refractory and N = 48 Acalabrutinib monoherapy Safety • FPD: Q1 2015 15-H-0016 treatment naive/del17p • Arm A: Lymph node biopsy CLL/small lymphocytic • Arm B: Bone marrow biopsy • Estimated Completion: 2017 NCT02337829 lymphoma(SLL)

Phase II Relapsed/refractory Mantle N = 124 Acalabrutinib monotherapy ORR • FPD: Q1 2015 ACE-LY-004 Cell Lymphoma • LPCD: Q1 2016 • Enrolment complete NCT02213926 • Estimated Completion: H2 2016

Phase I/II CLL/SLL/Richter's N = 286 Acalabrutinib monotherapy Safety, PK, PD • FPD: Q1 2014 ACE-CL-001 transformation Dose escalation and expansion Secondary endpoints: ORR, DOR, and PFS • Estimated completion: 2019 NCT02029443

Phase I/II B-Cell Malignancies N = 126 • Dose escalation and expansion study of the combination of Safety • FPD: Q1 2015 ACE-LY-001 acalabrutinib and ACP-319 (Pi3K inhibitor) ORR • Estimated completion: 2017 NCT02328014

Phase I/II Hematological Malignancies N = 324 • Acalabrutinib + pemrolizumab Safety • FPD: Q1 2015 ACE-LY-005 • Estimated completion: 2018 NCT02362035

53 Lifecycle management Late-stage development Early development - IMED Acalabrutinib (ACP-196) Early development - MedImmune Haematological malignancies

Trial phase Patient population Number of patients Design Endpoint(s) Status

Phase I/II Waldenstrom N = 106 Acalabrutinib monotherapy ORR • FPD: Q3 2014 ACE-WM-001 Microglobulinemia • LPCD: Q4 2015 • Enrolment Complete NCT02180724 • Estimated completion: H2 2016

Phase Ib Relapsed/refractory de novo N = 21 Acalabrutinib monotherapy Safety • FPD: Q3 2014 ACE-LY-002 ABC Diffuse large B-cell • LPCD: Q2 2016 lymphoma • Enrolment Complete

NCT02112526 • Estimated completion: 2017

Phase Ib Mantle Cell Lymphoma N = 48 Acalabrutinib in combination with bendamustin and rituximab Safety • FPD estimated: Q2 2016 ACE-LY-106 • Arm A: Treatment naive • Arm B: Relapsed/refractory NCT02717624 • Estimated completion: 2021

Phase Ib Relapsed/refractory Multiple N = 40 • Arm A: Acalabrutinib Safety • FPD: Q1 2015 ACE-MY-001 Myeloma • Arm B: Acalabrutinib + dexamethasone

NCT02211014 • Estimated completion: 2017

Phase I Relapsed/refractory Follicular N = 36 • Arm A: Acalabrutinib Safety • FPD: Q1 2015 ACE-LY-003 Lymphoma • Arm B: Acalabrutinib + rituximab

NCT02180711 • Estimated completion: 2018

Phase I Relapsed/refractory chronic N = 12 Acalabrutinib in combination with ACP-319 Safety, PK, PD • FPD: Q3 2014 ACE-CL-002 lymphocytic leukaemia (CLL) Dose escalation • LPCD: Q3 2015 • Enrolment complete

NCT02157324 • Estimated completion: 2018

Phase I CLL/small lymphocytic N = 45 Acalabrutinib + obinutuzumab Safety • FPD: Q1 2015 ACE-CL-003 lymphoma/prolymphocytic • Arm A: Relapsed/refractory ORR • LPCD: Q1 2016 leukaemia • Arm B: Treatment naive • Enrolment complete

NCT02296918 • Estimated completion: 2018

54 Lifecycle management Late-stage development Early development - IMED Acalabrutinib (ACP-196) Early development - MedImmune Solid Tumours

Trial phase Patient population Number of patients Design Endpoint(s) Status

Phase II ≥ 2L advanced or metastatic N = 74 • Arm A: Pembrolizumab ORR • FPD: Q2 2015 ACE-ST-006 squamous cell carcinoma of • Arm B: Acalabrutinib + pembrolizumab the head and neck • Estimated completion: 2017 NCT02454179

Phase II ≥ 2L advanced or metastatic N = 74 • Arm A: Pembrolizumab ORR • FPD: Q2 2015 ACE-ST-007 NSCLC • Arm B: Acalabrutinib + pembrolizumab • Estimated completion: 2017 NCT02448303

Phase II Recurrent ovarian cancer N = 76 • Arm A: Acalabrutinib ORR • FPD: Q4 2015 ACE-ST-208 • Arm B: Acalabrutinib+ pembrolizumab • Estimated completion: 2017 NCT02537444

Phase II 1L metastatic pancreatic N = 120 • Arm A: Acalabrutinib + Nab-Paclitaxel+ Gemcitabine ORR • FPD: Q4 2015 ACE-ST-004 cancer • Arm B: Nab-Paclitaxel + Gemcitabine • Estimated completion: 2017 NCT02570711

Phase II ≥ 2L advanced or metastatic N = 77 • Arm A: Acalabrutinib Safety • FPD: Q2 2015 ACE-ST-003 pancreatic cancer • Arm B: Acalabrutinib + pembrolizumab • LPCD: Q1 2016 • Enrolment complete NCT02362048 • Estimated completion: 2017

Phase II Platinum-resistant urothelial N = 78 • Arm A: Pembrolizumab ORR • FPD: Q2 2015 ACE-ST-005 bladder cancer • Arm B: Acalabrutinib + pembrolizumab • LPCD: Q1 2016 • Enrolment complete NCT02351739 • Estimated Completion 2017

Phase Ib/II ≥ 2L glioblastoma multiforme N = 72 Acalabrutinib monotherapy Safety • FPD: Q1 2016 ACE-ST-209 • Arm A: 200 mg BID ORR • Arm B: 400 mg QD NCT02586857 • Estimated completion: 2018

55 Lifecycle management Late-stage development Early development - IMED Moxetumomab pasudotox (CD22 mAb) Early development - MedImmune Haematological malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Adults with relapsed or N = 77 • Multicentre, single-arm, open-label trial3 • Primary: Rate of durable CR: CR • FPD: Q2 2013 PLAIT refractory hairy cell leukemia maintained for > 180 days • LPCD: H2 2016 (HCL) • Efficacy: CR rate, ORR, Duration of CR • Estimated top-line results: 2017 NCT01829711 and ORR, time to response (TTR), PFS • Safety and tolerability • PK and immunogenicity

Phase I Adults with relapsed refractory N = 49 • Open Label dose escalation trial • MTD and efficacy • FPD: Q2 2007 HCL • LPCD: Q1 2014 NCT00586924 • Top-line results : Q2 2015 (completed)

56 Lifecycle management Late-stage development Early development - IMED CAZ AVI (BLI/cephalosporin SBI) Early development - MedImmune Serious infections

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Hospitalised patients with N = 493 • Arm 1: CAZ AVI 2000/500mg plus Metronidazole IV • Co primary of: • FPD: Q1 2012 RECLAIM-1 complicated intra-abdominal • Arm 2: Meropenem IV (i) clinical response at TOC (MITT) • LPCD: Q2 2014 infections (ii) clinical response at TOC (i.e. • Top-line results: Q3 2014 NCT01499290 Global study – 20 countries clinically evaluable)

Phase III Hospitalised patients with N = 577 • Arm 1: CAZ AVI 2000/500mg plus Metronidazole IV • Co primary of: • FPD: Q2 2012 RECLAIM-2 complicated intra-abdominal • Arm 2: Meropenem IV (i) clinical response at TOC (MITT) • LPCD: Q2 2014 infections (ii) clinical response at TOC (i.e. • Top-line results: Q3 2014 NCT01500239 Global study – 21 countries clinically evaluable)

Phase III Hospitalised adults with N = 563 • Arm 1: CAZ AVI 2000/500mg IV plus either 500 mg of oral • Per patient microbiological response at • FPD: Q4 2012 RECAPTURE-1 complicated urinary tract ciprofloxacin or 800 mg/160 mg of oral TOC in patients with a cUTI and a Gram- • LPCD: Q3 2014 Infections sulfamethoxazole/trimethoprim negative pathogen (i.e. mMITT) • Top-line results: Q3 2015 NCT01595438 • Arm 2: Doripenem 500 mg IV plus either 500 mg of oral ciprofloxacin or 800 mg/160 mg of oral sulfamethoxazole/trimethoprim

Global trial – 26 countries

Phase III Hospitalised patients with N = 583 • Arm 1: CAZ AVI 2000/500mg IV plus either 500 mg of oral • Per patient microbiological response at • FPD: Q4 2012 RECAPTURE-2 complicated urinary tract ciprofloxacin or 800 mg/160 mg of oral TOC in patients with a cUTI and a Gram- • LPCD: Q3 2014 infections sulfamethoxazole/trimethoprim negative pathogen (i.e. mMITT) • Top-line results: Q3 2015 NCT01599806 • Arm 2: Doripenem 500 mg IV plus either 500 mg of oral ciprofloxacin or 800 mg/160 mg of oral sulfamethoxazole/trimethoprim

Global trial – 25 countries

Phase III Patients with complicated N = 345 • Arm 1: CAZ AVI 2000/500mg plus Metronidazole IV • Patients with clinical cure at the Test of • FPD: Q1 2013 REPRISE urinary tract infections and • Arm 2: Best available therapy Cure visit in the microbiological intent to • LPCD: Q3 2014 complicated intra-abdominal treat analysis set • Top-line results: Q2 2015 NCT01644643 infections Global trial – 30 countries

57 Lifecycle management Late-stage development Early development - IMED CAZ AVI (BLI/cephalosporin SBI) Early development - MedImmune Serious infections

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Hospitalised patients with N = 486 • Arm 1: CAZ AVI 2000/500mg plus Metronidazole IV • Clinical Cure at the TOC visit in the • FPD: Q1 2013 RECLAIM-3 complicated intra-abdominal • Arm 2: Meropenem IV MITT analysis set • LPCD: Q1 2015 infections • Top-line results: Q3 2015 NCT01726023 Asia-focused trial – three countries (China, Vietnam & Korea)

Phase III Hospitalised patients with N = 1,000 • Arm 1: CAZ AVI 2000/500mg IV • Proportion of patients with clinical cure • FPD: Q2 2013 REPROVE nosocomial pneumonia • Arm 2: Meropenem IV at the TOC visit in the cMITT and CE • LPCD: Q4 2015 infections, including hospital analysis sets (co-primary analyses) • Estimated top-line results: H2 2016 NCT01808092 acquired pneumonia (HAP) Global trial – 24 countries and ventilator associated pneumonia (VAP)

58 Lifecycle management Late-stage development Early development - IMED AZD3293 (BACE inhibitor) Early development - MedImmune Alzheimer’s disease

Trial phase Patient population Number of patients Design Endpoints Status

Phase III Early Alzheimer’s disease N = 2,202 • Arm 1: AZD3293 20 mg once daily • Changes in cognitive (ADAS-Cog 13) • FPD: Q4 2014 AMARANTH patients • Arm 2: AZD3293 50 mg once daily and functional (ADCS-ADL) scales • LPCD: 2017 • Arm 3: placebo once daily • Changes in composite scales (CDR-SB) • Estimated top-line results: 2019 NCT02245737 • Changes in biomarkers and imaging 24-month treatment duration assays • Safety and tolerability Global trial – 14 countries

59 AstraZeneca

Early development - IMED Lifecycle management Late-stage development Early development - IMED Verinurad (RDEA3170 - SURI, URAT1 inhibitor) Early development - MedImmune Gout and hyperuricemia development programme

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Monotherapy study in N = 160 • Arm A: Placebo • Efficacy and Safety at Week 24 • FPD: Q3 2013 subjects with gout • Arm B: Verinurad 5 mg QD • LPCD: Q4 2013 NCT01927198 • Arm C: Verinurad10 mg QD • Study complete • Arm D: Verinurad12.5 mg QD

Phase II Monotherapy study in N = 200 • Arm A: Placebo • To compare the efficacy of verinurad • FPD: Q1 2014 Japanese patients with • Arm B: Verinurad 5 mg QD monotherapy at Week 16 with placebo • LPCD: Q3 2014 NCT02078219 gout or asymptomatic • Arm C: Verinurad 10 mg QD and allopurinol • Study complete hyperuricemia • Arm D: Verinurad 12.5 mg QD • Arm E: Open-label Allopurinol 100mg BID

Phase II Combination therapy study N = 60 • Arm A: Verinurad 2.5 mg QD • To assess the PK and PD profiles of • FPD: Q4 2014 with febuxostat in subjects • Arm B: Verinurad 5.0 mg QD verinurad administered with febuxostat • LPCD: Q2 2015 NCT02246673 with gout • Arm C: Verinurad 10 mg QD • Estimated completion: Q2 2016 • Arm D: Verinurad 15 mg QD • Arm E: Sequential doses of verinurad 10, 15 and 20 mg QD in combination with 40 mg QD febuxostat

*Arms A-D include combination with 40 mg QD febuxostat for 7 days followed by combination with 80 mg QD febuxostat for 7 days

Phase II Combination study with N = 92 • Arm A: Verinurad 2.5 mg QD + 10mg or 20mg QD febuxostat • To assess the PD, PK and safety • FPD: Q4 2014 febuxostat for treating gout • Arm B: Verinurad 5.0 mg QD + 10mg or 20mg QD febuxostat profiles of verinurad administered with • LPCD: Q2 2015 NCT02317861 or asymptomatic • Arm C: Verinurad 5.0 mg QD + 20mg or 40mg QD febuxostat febuxostat • Estimated completion: Q2 2016 hyperuricemia in Japanese • Arm D: Verinurad 10 mg QD + 20mg or 40mg QD febuxostat patients • Arm E: Benzbromarone 50 mg QD

61 Lifecycle management Late-stage development Early development - IMED Verinurad (RDEA3170 - SURI, URAT1 inhibitor) Early development - MedImmune Gout and hyperuricemia

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Combination therapy N = 40 • Arm A: Placebo • To assess the PK and PD profiles of • FPD: Q3 2015 study with allopurinol in • Arm B: Verinurad 2.5 mg QD verinurad administered with allopurinol • LPCD: Q4 2015 NCT02498652 subjects with gout • Arm C: Verinurad 5.0 mg QD • Estimated completion: H2 2016 • Arm D: Verinurad 7.5 mg QD • Arm E: Verinurad 10 mg QD • Arm F: Verinurad 15 mg QD • Arm G: Verinurad 20 mg QD *All arms include combination with 300 mg QD allopurinol. Placebo group also includes combination with 300 mg BID allopurinol or 600 mg QD allopurinol

Phase I Pharmacokinetic and N = 40 Part 1: Single doses of verinurad at 4.5 mg, 6.0 mg, or 12 mg • To assess the PK, PD and food effect • FPD: Q4 2015 Pharmacodynamic study Part 2: Multiple doses of verinurad at 12 mg QD for 7 days profiles of verinurad • LPCD: Q4 2015 NCT02608710 in healthy adult male Part 3: Food effect study with single doses of verinurad at 6.0 mg • Estimated completion: H2 2016 subjects

62 Lifecycle management Late-stage development Early development - IMED AZD7594 (inhaled SGRM) Early development - MedImmune Asthma/COPD

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Patients with mild to moderate N = 48 A randomised, double blind, multiple dosing (14 days), placebo- • Forced expiratory volume in one second • FPD: Q3 2015 asthma controlled, incomplete block crossover, multi centre study to assess (FEV1) • Completed NCT02479412 efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild to moderate asthma

Phase I Healthy subjects N = 73 SAD/MAD • Safety and tolerability • FPD: Q4 2012 NCT01636024 A Phase I, Single Centre, Double-blind, Randomised, Placebo • Completed controlled, Parallel-group trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers - Suspension inhaled via Spira nebuliser

Trial conducted in the UK

Healthy subjects N = 24 An open label, partially randomised, four-period study in healthy • Bioavailability and pharmacokinetics • FPD: Q1 2016 Phase I male subjects to investigate the bioavailability and • Estimated completion: Q2 2016 NCT02648438 pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two different dry powder inhalers (DPI) and a pressurised metered-dose inhaler (pMDI)

Phase I Healthy subjects N = 36 A phase I, randomised, single-blind, placebo-controlled, • Safety and tolerability • FPD: Q1 2016 NCT02645253 sequential-group, single-centre study to investigate the safety, • Estimated completion: Q2 2016 tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of AZD7594 given once daily as inhaled formulation in healthy Japanese men

63 Lifecycle management Late-stage development Early development - IMED AZD7624 (p38 inhibitor) Early development - MedImmune Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIa COPD N = 212 • Arm 1: AZD7624, 1.0mg • Effect on rate of exacerbations and lung • FPD: Q4 2014 • Arm 2: placebo function compared to placebo • LPCD: Q1 2016 NCT02238483 • Inhaled (nebulised) administration • Estimated top-line results: Q2 2016

Trial conducted in US, EU, South Africa & South America

Phase Ib Healthy subjects N = 30 • 2-way cross-over RCT • Effect on neutrophils in induced sputum • FSD: Q4 2013 LPS • Single administration of 1200μg of AZD7624 or placebo at 0.5 after oral inhalation of LPS, compared to • Completed hours prior to lipopolysaccharide (LPS) challenge. placebo NCT01937338 • Inhaled (nebulised) administration

Trial conducted in the UK

Phase I Healthy subjects N = 48 SAD • Safety and tolerability following inhaled • FSD: Q1 2013 • Five different dose levels investigated vs placebo administration with single ascending • Completed NCT01754844 • Inhaled (nebulised) administration dose

Trial conducted in the UK

Phase I Healthy subjects and COPD N = 47 MAD • Safety and tolerability in healthy subjects • FSD: Q3 2013 • Different dose levels investigated vs placebo in healthy and patients with COPD following • Completed NCT01817855 volunteers and patients with COPD administration of multiple ascending • Inhaled (nebulised) administration inhaled doses

Trial conducted in the UK

64 Lifecycle management Late-stage development Early development - IMED AZD7986 (DPP1 inhibitor) Early development - MedImmune Chronic Obstructive Pulmonary Disease

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy subjects N = 152 Part 1 (SAD) • Safety and tolerability and PK following • FPD: Q4 2014 • Five different dose levels investigated vs placebo oral administration with single ascending • Completed NCT02303574 • oral administration dose • Preliminary assessment of the effect of food on the single dose PK parameters of AZD7986

Part 2 (MAD) • Safety and tolerability & PK in healthy • FPD: Q1 2015 • Three different dose levels investigated vs placebo in healthy subjects following administration of • LPCD: Q1 2016 volunteers multiple ascending oral doses • Estimated completion: Q2 2016 • oral administration • NE activity

Trial conducted in the UK

65 Lifecycle management Late-stage development Early development - IMED AZD8871 (MABA2) Early development - MedImmune Asthma/Chronic Obstructive Pulmonary Disease (COPD)

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Part 1: Mild Asthmatic N (Part 1) = 16 Part 1 Part 1 Endpoints: Part 1 SAD trial with 6 planned dose levels - 50 μg, 100 μg, 300 μg, 600 • To assess the safety and tolerability of • FPD: Q4 2015 CTs.gov Identifier: Part 2: Moderate to severe N (Part 2) = 40 μg, 1200 μg, and up to 1800 μg single doses of AZD8871 administered • LPCD: Q1 2016 In progress COPD by inhalation to mild persistent asthmatic Part 2 male subjects Part 2 Comprises 5 treatment periods of 36 hours each separated by a • To evaluate the pharmacodynamics • FPD: Q2 2016 washout period of at least 7 to 14 days (one exception per patient (PD) (bronchodilation) of single doses of • LPCD: H2 2016 of up to 28 days would be acceptable). AZD8871 in mild persistent asthmatic male subjects • AZD8871 dose A once daily (double-blind) • Estimated completion date: 2017 • AZD8871 dose B once daily (double-blind) Part 2 Endpoints: • Indacaterol 150 μg once daily (open-label) • To assess the safety and tolerability of • Tiotropium 18 μg once daily (open-label) single doses of AZD8871 administered • Placebo (double-blind) by inhalation to moderate to severe COPD subjects Global trial – one country • To evaluate the pharmacodynamics (PD) (bronchodilation) of single doses of AZD8871 in moderate to severe COPD subjects

66 Lifecycle management Late-stage development Early development - IMED AZD9412 (Inhaled IFN-beta) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIa Asthma N = 220 • Arm 1: 24 μg (metered dose) AZD9412 once daily for 14 days • Proportion of patients with a severe • FPD: Q3 2015 INEXAS • Arm 2: Placebo once daily for 14 days asthma exacerbation during 14 days of • LPCD: H2 2016 • Inhaled nebulised administration treatment • Estimated top-line results: 2017 NCT02491684 Conducted in Argentina, Australia, Colombia, France, Spain, South Korea and UK.

67 Lifecycle management Late-stage development Early development - IMED AZD9567 (oSGRM) Early development - MedImmune Rheumatoid Arthritis

Trial phase Patient population Number of subjects Design Endpoints Status

Phase I Healthy Volunteers N = 72 SAD trial with 6 dose levels - 2 μg, 10 μg, 40 μg, 100 μg, • A Phase I, Randomised, Single-Blind, Part NCT02512575 200 μg, and up to 400 μg Placebo-Controlled trial To Assess The • FPD: Q4 2015 Safety, Tolerability, Pharmacokinetics • LPCD: Q2 2016 And Pharmacodynamics Of Single • Estimated top-line results: H2 2016 Global trial – one country Ascending Oral Doses Of AZD9567 In Healthy subjects

68 Lifecycle management Late-stage development Early development - IMED AZD4076 (anti-miR 103/107) Early development - MedImmune Non-alcoholic Steatohepatitis (NASH)

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy subjects N = up to 48 SAD trial • Safety and tolerability • FPD: Q4 2015 • Up to 6 different dose levels investigated vs placebo • PK parameters • LPCD: H2 2016 NCT02612662 • Sub cutaneous injection • Estimated completion: 2017

69 Lifecycle management Late-stage development Early development - IMED AZD0156 (ATM) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Solid tumours N = 130 • Arm 1: AZD0156 + olaparib • Safety, tolerability, pharmacokinetics • FPD: Q4 2015 • Arm 2: AZD0156 + irinotecan and efficacy • Estimated completion: 2018 NCT02588105

Trial conducted in North America, Europe and South Korea

70 Lifecycle management Late-stage development Early development - IMED AZD1775 (WEE-1) Early development - MedImmune Solid tumours, ovarian cancer and Non-Small Cell Lung Cancer

Trial phase Patient population Number of patients Design Endpoints Status

Phase II p53 mutant PSR ovarian N = 120 • Arm 1: Carbo/paclitaxel + AZD1775 225mg • PFS • FPD: Q4 2012 cancer • Arm 2: Carbo/paclitaxel + placebo • Secondary endpoint: OS • LPCD: H2 2016 NCT01357161 • Estimated completion: H2 2016 (OS Global trial 10 countries Follow up) Partnered • Note: Data collection for primary outcome measure completed Q4 2014

Phase II PR ovarian cancer N = 70 • Arm C: Carboplatin + AZD1775 • Overall Response Rate (ORR) • FPD: Q1 2015 • Arm D: Pegylated liposomal doxorubicin (PLD) + AZD1775 • Secondaries : Duration of Response • LPCD: H2 2016 NCT02272790 (DOR), PFS, OS, Disease Control Rate, • Estimated completion: H2 2016 Global trial safety and tolerability

Phase I/II Advanced solid tumours N = 152 • Monotherapy • Safety and tolerability • FPD: Q3 2015 Safety Run-in (part A, N=12); solid tumours • Secondary endpoints: Overall response • LPCD: 2017 NCT02482311 Expansions into specific tumour types, inc ovarian cancer rate, Disease Control Rate, Duration or • Estimated completion: 2017 (BRCAm PARP failures and BRCAwt with three or more prior Response, PFS lines of treatment), triple negative breast cancer (TNBC) and small cell lung cancer (SCLC)

Conducted in US, Canada

Phase I Advanced solid tumours N = 18 • Monotherapy • Safety and tolerability • FPD: Q4 2015 Dose escalation trial to determine MTD • LPCD: H2 2016 NCT02610075 • Estimated completion: 2017 Conducted in US

Phase I Advanced solid tumours N = 36 • Dose escalation trial (AZD1775 + olaparib) • Safety and tolerability • FPD: Q3 2015 • LPCD: Q1 2016 NCT02511795 Conducted in US • Estimated completion: Q2 2016

Phase I Advanced solid tumours N = 18 • Dose escalation trial (AZD1775 + MEDI4736) • Safety and tolerability • FPD: Q4 2015 • LPCD: H2 2016 NCT02617277 Conducted in US • Estimated completion: 2017

Phase I Advanced solid tumours N = 36 • Dose escalation trial (AZD1775 + carboplatin + paclitaxel: • Safety and tolerability • FPD: Q1 2015 AZD1775 + Carbo: AZD1775 + PLD) • LPCD: H2 2016 NCT02341456 • Estimated completion: 2017 Conducted in Australia, Japan and Republic of Korea

71 Lifecycle management Late-stage development Early development - IMED AZD2014 (TORC 1/2) Early development - MedImmune Breast and squamous Non-Small Cell Lung Cancer (NSCLC)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIa Relapsed or refractory N = 40 Open label • Primary: ORR according to RECIST 1.1 • FPD: Q2 2015 STORK squamous NSCLC (at least by Investigator assessment • LPCD: H2 2016 one prior therapy) Single arm – patient are divided in two groups • Secondary: Number of patients • Estimated completion: H2 2016 NCT02403895 Group A - intensive PK experiencing adverse events (AE) and Group B – sparse PK Serious Adverse Events (SAEs) including chemistry, haematology, vital Dose: intermittent AZD2014 50mg BID (3 days on + 4 days off) + signs and ECG variables weekly paclitaxel 80 mg/m2

Multicentre: EU and US trial sites

Phase II 2L ER+ metastatic breast N = 316 • Arm 1: Faslodex • PFS • FPD: Q2 2014 MANTA cancer • Arm 2: Faslodex + AZD2014 50mg BD continuous dosing • Secondary endpoint: OS • LPCD: Q2 2016 • Arm 3: Faslodex + AZD2014 125mg BD two days on, 5 off • Estimated completion: 2017 NCT02216786 • Arm 4: Faslodex + everolimus

Partnered The trial will be conducted in Europe

Phase I Japanese Patients with N = 18 Open label • Safety and tolerability of AZD2014 • FPD: Q2 2015 Advanced Solid Malignancies monotherapy and in combination with • LPCD: 2017 NCT02398747 Monotherapy and combination with paclitaxel cohorts paclitaxel • Estimated completion: 2017 • PK

Phase I/II Postmenopausal women with N = 225 Part A - Phase I triplet dose finding to determine the maximum Primary • FPD: Q1 2016 PASTOR locally advanced/metastatic tolerated dose (MTD) of the triplet (AZD2014 + palbociclib + • Part A:Safety and tolerability of the • LPCD: 2018 estrogen receptor positive fulvestrant) triplet. MTD and recommended dose for • Estimated completion: 2019 NCT02599714 (ER+) breast cancer. Parts B and C Part B - Phase I single arm expansions (AZD2014 + palbociclib + • Part B: Safety and tolerability Faslodex) • Part C: PFS Secondary: Best Objective Response Rate Part C - randomised, double-blind, placebo-controlled, stratified, (BOR) and Objective Response Rate parallel group extension at RP2D for triplet combination (ORR) (AZD2014 + palbociclib + Faslodex vs matching AZD2014 placebo + palbociclib + Faslodex)

72 Lifecycle management Late-stage development Early development - IMED AZD2811 (AURN) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Solid tumours N = 72 • Arm 1: AZD2811 dose escalation • Safety and tolerability • FPD: Q4 2015 • Arm 2: AZD2811 dose expansion • Pharmacokinetics and efficacy • Estimated completion: 2017 NCT02579226 AZD2811 + irinotecan

Trial conducted in North America

73 Lifecycle management Late-stage development Early development - IMED AZD3759 (EGFRm BBB) Early development - MedImmune Non-Small Cell Lung Cancer (NSCLC) with lung and/or brain metastases

Trial phase Patient population Number of patients Design Endpoints Status

Phase I EGFRm+ NSCLC N = 47 • MAD • Safety and tolerability • FPD: Q4 2014 BLOOM • Expansion in LM patients at RP2D with AZD3759 • Preliminary anti-tumour activity • Estimated completion: LM expansion at • Expansion in 12 LM patients at 160mg with AZD9291 including RP2D NCT02228369 cohort with T790M NSCLC H2 2016 • AZD9291 LM expansion Trial conducted four countries • Estimated primary completion: H2 2016

74 Lifecycle management Late-stage development Early development - IMED AZD4547 (FGFR) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase II/III Lung Master Stage IIIB-IV NSCLC patients N = 318 (AZD4547 6-Arm trial based on biomarker expression • PFS • FPD: Q4 2014 Protocol arm only) • Arm 1: MEDI4736 Unmatched biomarker • OS • Estimated completion: 2022 Biomarker-targeted • Arm 2: AZD4547 (FGFR inhibitor) (final data collection for primary NCT02154490 2L therapy • Arm 3: CDK4/6 inhibitor outcome measure Ph III) • Arm 4: PI3K Inhibitor Partnered with NCI and • Arm 5: HGFR Inhibitor SWOG • Arm 6: CTLA-4 + PD-1 inhibitor

Phase II Female ER+ breast cancer N = 40 • Part A: AZD4547 in ascending multiple doses in combination • Part A: MTD of AZD4547 in • LPCD: Q2 2014 GLOW patients whose disease has with 25mg exemestane combination with 25mg exemestane in • Completed: Q1 2015 progressed following • Part B: three schedules of AZD4547 NCT01202591 treatment with one prior • Arm 1: AZD4547 (dose from part A) + Faslodex • Part B Interim analysis: Tumour size endocrine therapy • Arm 2: placebo + Faslodex analysis on 30 FGFR amplified patients • Part B Final analysis: PFS Patients with FGFR1 polysomy (30 patients) or FGFR1 amplification (60 patients)

Phase II Advanced gastro- N = 71 • Arm 1 (FGFR2 polysomy): AZD4547 vs paclitaxel randomised • PFS • Recruitment closed after interim SHINE oesophageal cancer 1:1 (30 to 80 patients) • Key Secondary: OS/Tumour size analysis: Q2 2013 • Arm 2 (FGFR 2 low gene amplification: AZD4547 vs paclitaxel • Completed: Q1 2015 NCT01457846 randomised 3:2 (25 to 80 patients) • Arm 3 (FGFR2 high gene amplification: AZD4547 vs paclitaxel randomised 3:2 (25 to 80 patients)

Phase I Advanced cancer who have N = 33 • Part A: AZD4547 in ascending multiple doses given bd and od • Part A: MTD and Recommended dose • Completed: Q2 2013 failed standard therapy or for (c. 30 patients) for Parts B and C NCT01213160 whom no standard therapy • Part B: AZD4547 in patients whose tumours have FGFR • Part B: Safety and tolerability and exists amplification (c. 8 patients) preliminary anti-tumour activity

Conducted in Japan

75 Lifecycle management Late-stage development Early development - IMED AZD4547 (FGFR) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced cancer who have N = 94 • Part A: Ascending oral doses of AZD4547 to define maximum • Part A: MTD and Recommended dose • Completed: Q1 2014 failed standard therapy or for tolerated dose (MTD) and /or continuous, tolerable for Parts B and C NCT00979134 whom no standard therapy recommended dose (RD) • Part B and C: Safety and tolerability, exists • Part B: Dose expansion phase at RD defined in Part A PK and preliminary anti-tumour activity • Part C: Expansion phase in patiens with FGFR1 and FGFR2 amplified tumours at the RD defined from Part A

nd Phase I 2 + line Muscle Invasive N = 140 • Multi-drug biomarker-directed trial • Safety and tolerability of the • FPD: Q2 2016 BISCAY Metastatic Bladder Cancer in • Monotherapy: AZD4547, durvalumab combinations • Estimated completion: 2018 patients who have failed prior • Combination therapy: AZD4547 + durvalumab, Lynparza + • PK and preliminary anti-tumour activity NCT02546661 therapy durvalumab, AZD1775 + durvalumab

76 Lifecycle management Late-stage development Early development - IMED AZD5363 (AKT) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIb ER+ breast cancer receiving N = 100 • Arm 1: AZD5363 + paclitaxel • PFS • FPD: Q1 2014 1st treatment with paclitaxel in • Arm 2: AZD5363 placebo + paclitaxel • Response rate (ORR) & OS are • Estimated primary completion: H2 2016 NCT01625286 the advanced setting secondary endpoints • Estimated completion: 2017 Two strata (50 pts per stratum): PIK3CA mutation positive vs Mutation not detected

Phase I Breast and gynaecological N = 20 per arm Monotherapy AZD5363 480mg BD 4 days on 3 days off • Safety and tolerability • FPD: Q3 2013 cancers with PIK pathway (Parts C & D) • Part C arm 1: Breast with PIK3CA mutation • Response Rate (ORR) • Estimated primary completion: H2 17 NCT01226316 mutation • Part C arm 2: Gynaecological with PIK3CA mutation • Clinical Benefit Rate at 24 wks (CBR24) • Part C Arms 1 & 2 completed N = 12-24 per arm • Part D arm 1: Breast with AKT-1 mutation [Parts E & F only] • Part D Arms 1 & 3 completed (Parts E & F) • Part D arm 2: Gynaecological with AKT-1 mutation • Part D Arm 2 ongoing • Part D arm 3: Other tumours with AKT-1 mutation • Part E Arms 1 & 2 ongoing [CBR24 data for 12 patients per arm AZD5363 400mg BD 4 days on 3 days off combined with 500mg estimated Q2/Q3 2017] fulvestrant [initially 12 patients per arm with option to expand to • Part F Arms 1 & 2 ongoing 24 patients in one or more arms] • Part E arm 1: ER+ Breast with AKT-1 mutation (prior Faslodex resistance) • Part E arm 2: ER+ Breast with AKT-1 mutation (first exposure to Faslodex) • Part F arm 1: ER+ Breast with PTEN mutation (prior Faslodex resistance) • Part F arm 2: ER+ Breast with PTEN mutation (first exposure to Faslodex)

77 Lifecycle management Late-stage development Early development - IMED Savolitinib (AZD6094) (MET) Early development - MedImmune Papillary renal cell and other cancers

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Papillary renal cell cancer N = 90 • Single arm trial: AZD6094 600mg QD • Overall Response Rate • FPD: Q2 2014 • LPCD: H2 2016 NCT02127710 Conducted in UK, Spain, US, Canada • Estimated completion: 2017

Phase I Advanced cancer N = 50 • Dose escalation trial • Safety and tolerability • FPD: Q1 2012 (all-comers) • LPCD: Q3 2015 NCT01773018 Conducted in Australia • Estimated completion: Q2 2016

Partnered

Phase I Advanced cancer N = 70 • Dose escalation trial • Safety and tolerability • FPD: Q2 2013 (all comers) • LPCD: H2 2016 NCT01985555 Conducted in China • Estimated completion: 2017

Partnered

Phase I Advanced gastric cancer N = 25 • Dose escalation trial • Safety and tolerability • FPD: Q4 2014 (all-comers) • LPCD: Q4 2015 NCT02252913 Conducted in China • Estimated completion: Q2 2016

Partnered

Phase I Non-Small Cell Lung Cancer N ~ 32 • Dose escalation trial • Safety and tolerability • FPD: Q2 2015 • LPCD: H2 2016 NCT02374645 Conducted in China • Estimated completion: 2017

78 Lifecycle management Late-stage development Early development - IMED AZD6738 (ATR) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Solid tumours N = 160 • Arm 1: AZD6738 + carboplatin • Safety and tolerability • FPD: Q4 2014 • Arm 2: AZD6738 dose escalation • Pharmacokinetics and efficacy • Estimated completion: 2017 NCT02264678 AZD6738 + olaparib • Arm 3: AZD6738 + durvalumab

Trial conducted in North America, Europe and South Korea

79 Lifecycle management Late-stage development Early development - IMED AZD8186 (PI3Kb/d) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced Castrate Resistant N = 153 • Part A: AZD8186 monotherapy in ascending intermittent doses • Part A: PK, MTD and Recommended • FPD: Q2 2013 Prostate Cancer /sqNSCLC in 3 schedules dose and schedule(s) for Part B • Estimated completion: 2018 NCT01884285 /TNBC and patients with known PTEN-deficient/ • Part B: AZD8186 monotherapy at recommended dose and • Part B: Safety, tolerability and mutated or PIK3CM mutated/ schedule(s) from Part A in PTEN deficient patients with preliminary assessment of antitumour amplified advanced solid advanced cancer activity (POM) malignancies. • Part C: Combination AZD8186 added to abiraterone actetate • Part C: PK, safety, tolerability and (with prednisone) in PTEN deficient mCRPC patients. Initial recommended dose/ schedule of dose/ schedule confirmation phase using AZD8186 AZD8186 in combination with mononotherapy recommended dose/ schedule from Part A and abiraterone. Preliminary assessment of the labelled dose of abiraterone followed by an expansion antitumour activity of AZD8186 in cohort to explore clinical activity. combination with abiraterone.

• Part D: Combination AZD8186 and AZD2014 (a novel dual • Part D: PK, safety, tolerability and mTORC 1/2 inhibitor). Initial dose/ schedule determination recommended dose and schedule of phase in same patient population as Part A followed by an AZD8186 in combination with AZD2014. expansion cohort in PTEN deficient TNBC patients to explore Preliminary assessment of antitumour clinical activity. activity of AZD8186 in combination with AZD2014. Trial conducted in Canada, US, Spain & UK

80 Lifecycle management Late-stage development Early development - IMED AZD9150 (STAT3) Early development - MedImmune Solid and Haematological Cancers

Trial phase Patient population Number of patients Design Endpoints Status

Phase Ib/II Squamous Cell Carcinoma of N = 147 Dose Escalation advanced solid and haematological cancers • Safety/Efficacy trial • FPD: Q3 2015 the Head & Neck (SCCHN) • Arm A1: AZD9150/MEDI4736 • LPCD: 2017 NCT02499328 • Arm A2 : AZD5069/MEDI4736 • Estimated completion: 2019 Dose Expansion 2L SCCHN: • Arm B1: AZD9150 • Arm B2: AZD5069 • Arm B3: AZD9150/MEDI4736 • Arm B4: AZD5069/MEDI4736

* clinicaltrials.gov being updated 81 Lifecycle management Late-stage development Early development - IMED AZD9496 (SERD) Early development - MedImmune Breast cancer

Trial phase Patient population Number of patients Design Endpoints Status

Phase I ER+ Breast Cancer N ~ 150 • This is a Phase I open label multicentre trial of AZD9496 • Primary Outcome Measures: Safety and • FPD: Q4 2014 administered orally in patients with advanced ER+ HER2 tolerability • Estimated completion: 2017 NCT02248090 negative breast cancer. The trial design allows an escalation of • Secondary Outcome Measures: Single dose with intensive safety monitoring to ensure the safety of and multiple dose pharmacokinetics of patients. The trial will determine the maximum tolerated dose. AZD9496 In addition, expansion cohort(s) at potential therapeutic 4β-hydroxycholesterol concentration in dose(s) in patients with or without ESR1 mutations will be blood enrolled to further determine the safety, tolerability, • Anti-tumour activity pharmacokinetics and biological activity of AZD9496

82 Lifecycle management Late-stage development Early development - IMED ATM AVI Early development - MedImmune Infections

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers • Randomised, double-blind, 3-part trial in healthy young and • Safety/tolerability • FPD Q4 2012 elderly volunteers given Aztreonam and Avibactam alone and • Pharmacokinetics (secondary) • LPCD: Q4 2014 NCT01689207 in combination • Completion: Q4 2015

N = 12 • Part A: single 1 hour IV infusions

N = 56 • Part B: single IV infusion on Days 1 and 11 and multiple (every 6 hr) IV infusions on Days 2-10. Various dose regimens of Aztreonam-Avibactam are being tested.

N = 24 • Part C: multiple (every 6 hr) IV infusions Days 1-10 in healthy young and elderly volunteers

(Total dosed = 94) Single centre in UK (Total enrolled = 124)

83 Lifecycle management Late-stage development Early development - IMED AZD3241 (MPO) Early development - MedImmune Multiple System Atrophy (MSA)

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Parkinson’s disease patients N = 24 • Arm 1: AZD3241 600 mg BID for 8 weeks • Microglia activation represented by • Trial completed • Arm 2: Placeb0 [11C]PBR28 binding NCT01527695 Secondary endpoints: Randomisation 3:1 active to placebo. • PD symptoms measured by UPDRS Three sites in Sweden and Finland • Plasma MPO activity

Phase II Parkinson’s disease patients N = 51 • Arm 1: AZD3241 300 mg BID for 12 weeks • AEs, labs, vital signs, ECGs • Trial completed • Arm 2: AZD3241 600 mg BID for 12 weeks NCT01603069 • Arm 3: Placebo Secondary endpoints: • PD symptoms measured by UPDRS Randomisation 1:1:1 across arms • Plasma MPO activity 13 sites in US

Phase II MSA N = 54 • Arm 1: AZD3241 300 mg BID for 12 weeks • Microglia activation represented by • FPD: Q2 2015 • Arm 2: AZD3241 600 mg BID for 12 weeks [11C]PBR28 binding • LPCD: H2 2016 NCT02388295 • Arm 3: Placebo • AEs, labs, vital signs, ECGs • Estimated top-line results: H2 2016

Randomisation 1:1:1 across arms Secondary endpoints: Eight sites in US • MSA symptoms measured by UMSARS Nine sites in Europe and MSA QoL • Plasma MPO activity

Phase I Healthy subjects N = 46 • Active ArmS: SAD • AEs, labs, vital signs, ECGs • Trial completed • Comparator Arm: placebo • PK NCT00729443 One site in Sweden

Phase I Healthy subjects N = 18 • Active ArmS: MAD • AEs, labs, vital signs, ECGs • Trial completed • Comparator Arm: placebo • PK NCT01457807 One site in UK

Phase I Healthy subjects N = 59 • Active ArmS: MAD • AEs, labs, vital signs, ECGs • Trial completed • Comparator Arm: placebo • PK NCT00914303 One site in Sweden

84 Lifecycle management Late-stage development Early development - IMED AZD8108 (NMDA) Early development - MedImmune Phase I clinical development programme

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers N = 40 • Randomised, double-blind, placebo-controlled • Safety and tolerability • FPD: Q4 2014 • Part 1 SAD 3 dosage-level cohorts Additional endpoints: • LPCD: Q3 2015 NCT02248818 • Part 2 MAD 2 dosage-level cohorts • Pharmacokinetics • Estimated top-line results: Q2 2016 • Pharmacodynamics US only trial – one site

85 MedImmune

Early development - MedImmune Lifecycle management Late-stage development Early development - IMED Mavrilimumab (GMCSF mAb) Early development - MedImmune Rheumatoid arthritis (RA)

Trial phase Patient population Number of patients Design Endpoints Status

Phase II RA patients who have failed 1 N = 138 • Arm 1: Mavrilimumab SC • ACR 20/50/70 at wk 24 • FPD: Q1 2013 EARTH or 2 anti-TNF for efficacy, • Arm 2: Golimumab • DAS28 remission • LPCD: Q3 2014 Explorer 2 intolerance or safety, OR • Function (HAQ-DI) • Top-line results: Q4 2014 Inadequate response to Global trial (ex-US) on MTX background; 17 countries • Completed NCT01715896 DMARDs

Phase I Healthy Japanese subjects N = 24 • Arm 1: Mavrilimumab medium dose SC • Pharmacokinetic profile • FPD: Q3 2014 • Arm 2: Mavrilimumab high dose SC • Safety and tolerability • LPCD: Q3 2014 NCT02213315 • Arm 3: Placebo SC • Top-line results: Q4 2014 • Completed UK trial; Japanese subjects

87 Lifecycle management Late-stage development Early development - IMED MEDI5872 (B7RP-1 mAb) Early development - MedImmune Systemic Lupus Erythematosus (SLE)

Trial phase Patient population Number of patients Design Endpoints Status

Phase IIa Primary Sjögren's syndrome N = 42 • Arm 1: MEDI5872 210 mg SC QW for 3 weeks and then Q2W • Safety and tolerability • FPD: Q3 2015 for 9 weeks • Change in the ESSDAI score from • LPCD: 2017 NCT02334306 • Arm 2: placebo SC QW for 3 weeks and then Q2W for 9 weeks baseline to Day 99 • Estimated top-line results: 2017

Partnered Global trial – five countries

Phase I SLE and lupus related N = 40 Dose escalation trial: • Safety and tolerability • FPD: Q2 2012 inflammatory arthritis • Arm 1: MEDI5872 SC • Lupus Arthritis Response Rate • LPCD: Q4 2015 NCT01683695 • Arm 2: placebo SC • Estimated top-line results: Q2 2016

Partnered Global trial – eight countries

88 Lifecycle management Late-stage development Early development - IMED MEDI7836 (IL-13 mAb) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers N = 32 • Arm 1: 30 mg MEDI7836 (n = 6) or placebo (n = 2) as a single • Safety and tolerability • FPD: Q1 2015 SC dose • LPCD: Q3 2015 NCT02388347 • Arm 2: 105 mg MEDI7836 (n = 6) or placebo (n = 2) as a single • Top-line results: Q1 2016 SC dose • Arm 3: 300 mg MEDI7836 (n = 6) or placebo (n = 2) as a single SC dose • Arm 4: 600 mg MEDI7836 (n = 6) or placebo (n = 2) as a single SC dose

89 Lifecycle management Late-stage development Early development - IMED MEDI9929 (TSLP mAb) Early development - MedImmune Asthma

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Adult subjects with inadequately N = 552 • Arm 1: Placebo • Reduction in the annualised asthma exacerbation • FPD: Q2 2014 PATHWAY controlled, severe asthma • Arm 2: Low dose MEDI9929 70mg SC rate (AER) measured at Week 52 • LPCD: Q4 2015 • Arm 3: Medium dose MEDI9929 210mg SC • Estimated top-line results: H2 NCT02054130 • Arm 4: High dose MEDI9929 280mg SC 2016

Partnered

Phase II Adult subjects with moderate-to- N = 100 • Arm 1: Placebo • 50% reduction from baseline in the Eczema Area • FPD: Q2 2015 severe atopic dermatitis • Arm 2: Dose of MEDI9929 SC and Severity Index measured at Week 12 • LPCD: H2 2016 NCT02525094 • Estimated top-line results: H2 2016 Partnered

90 Lifecycle management Late-stage development Early development - IMED MEDI9314 (IL-4Ra mAb) Early development - MedImmune Atopic Dermatitis

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Healthy volunteers N = 44 • Arm 1: 45mg MEDI9314 (n = 4) or placebo (n = 2) as a single SC dose • Safety and tolerability • FPD: Q1 2016 NCT 02669667 • Arm 2: 150 mg MEDI9314 (n = 4) or placebo (n = 2) as a single SC dose • Pharmacokinetic profile • LPCD: H2 2016 • Arm 3: 300 mg MEDI9314 (n = 6) or placebo (n = 2) as a single SC dose • Incident of ADA antibodies to MEDI9314 • Estimated top-line results: • Arm 4: 300 mg MEDI9314 (n = 6) or placebo (n = 2) as a single IV dose • Change relative to baseline of IL-4-induced STAT6 H2 2016 • Arm 5: 300 mg MEDI9314 (n = 6) or placebo (n = 2) as a single SC dose phosphorylation (Japanese subjects) • Arm 6: 450 mg MEDI9314 (n = 6) or placebo (n = 2) as a single IV dose

91 Lifecycle management Late-stage development Early development - IMED Other biologics Early development - MedImmune Inflammation

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase II Anti-IL-23 mAb Patients with moderate N = 121 • Arm 1: MEDI2070, 700mg IV (210mg SC • CDAI response at Week 8 defined by • FPD: Q1 2013 MEDI2070 to severe Crohn’s for OLE) either a CDAI score of < 150 or a • LPCD: Q1 2014 NCT01714726 disease • Arm 2: Placebo, IV CDAI reduction from baseline of at • Top-line results: Q2 2014 least 100 points Partnered Global trial – nine countries

Phase II Patients with moderate N = 342 • Arm 1: MEDI2070 High dose • The primary endpoint is Crohn's • FPD: Q1 2016 to severe Crohn’s • Arm 2: MEDI2070 High-Med dose Disease Activity Index (CDAI) clinical • LPCD: 2019 NCT02574637 disease • Arm 3: MEDI2070 Low-Med dose remission at Week 8, defined by a • Estimated top-line results: 2018 • Arm 4: MEDI2070 Low dose CDAI score of <150. Partnered • Arm 5: Placebo

92 Lifecycle management Late-stage development Early development - IMED Other biologics Early development - MedImmune Autoimmunity

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase II/III Inebilizumab Adults with N = 212 (estimated) • Arm 1: MEDI-551 500mg IV • Primary: Time to attack • FPD: Q1 2015 Anti-CD19 mAb Neuromyelitis Optica • Arm 2: placebo IV • Secondary: Attack rate, safety and • LPCD: 2017 NCT02200770 (MEDI-551) and Neuromyelitis • Open-label extension 300mg tolerability • Estimated top-line results: 2018 Optica Spectrum Disorders Global trial (NMO/NMOSD) 26 Countries

Phase I Anti-CD40L Healthy adults N = 56 • Arm 1: 3 mg MEDI4920 • Safety, tolerability, and • FPD: Q2 2014 (MEDI4920) (n = 2) or placebo (n = 1) as a single IV dose pharmacokinetics, anti-drug antibody, • LPCD: Q4 2015 NCT02151110 • Arm 2: 10 mg MEDI4920 inhibition of T-cell dependent • Top-line results: Q1 2016 (n = 2) or placebo (n = 1) as a single IV dose antibody response • Arm 3: 30 mg MEDI4920 (n = 3) or placebo (n = 2) as a single IV dose • Arm 4: 100 mg MEDI4920 (n = 8) or placebo (n = 2) as a single IV dose • Arm 5: 300 mg MEDI4920 (n = 8) or placebo (n = 2) as a single IV dose • Arm 6: 1000 mg MEDI4920 (n = 8) or placebo (n = 2) as a single IV dose • Arm 7: 2000 mg MEDI4920 (n = 8) or placebo (n = 2) as a single IV dose

93 Lifecycle management Late-stage development Early development - IMED Biologics Early development - MedImmune Cardiovascular & metabolic disease

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase IIa rhLCAT Adults with stable N = 56 • SAD in stable CAD patients • Safety profile in terms of adverse • FPD: Q4 2015 MEDI6012 coronary artery disease events (AE), vital signs, ECG, • LPCD: Q1 2016 NCT02601560 (CAD) and low High- telemetry, lab variables, • Top-line results: Q1 2016 density lipoprotein immunogenicity and physical (HDL) examination • Changes in baseline adjusted post dose HDL-C

Phase I rhLCAT Adults with stable N = 16 SAD IV • Safety • Completed by Alphacore MEDI6012 coronary artery disease • Changes in total HDL NCT01554800 and low HDL • Change in Cholestryl Ester

Phase I rh-Factor II Healthy male subjects N = 12 SAD IV administration • Safety profile in terms of adverse • FPD: Q4 2013 MEDI8111 events (AE), vital signs, ECG, • LPCD: Q4 2014 NCT01958645 UK trial site telemetry, lab variables, • Completed: Q4 2014 immunogenicity and physical examination

Phase I GLP-1-Glu Healthy male subjects N = 64 SAD SC administration • Safety profile in terms of adverse • FPD: Q1 2015 MEDI0382 events (AE), vital signs, ECG, • LPCD: Q4 2015 NCT02394314 Germany telemetry, lab variables, nausea, • Top-line results: Q4 2015 immunogenicity and physical • Complete examination

Phase I/lla MEDI4166 Adults with type-2 N =124 SAD/MAD SC administration Part A (Ph1) • FPD: Q4 2015 diabetes • Safety/tolerability following SC • LPCD: H2 2016 NCT02524782 dosing of 4166 • Estimated top-line results: H2 2016 Part B (Ph2a) • Characterise the effect of multiple- ascending SC doses on glucose metabolism following an MMTT as measured by glucose AUC • Characterise the effect of multiple- ascending SC doses on LDL-c levels

94 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune Immuno-oncology

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase I/II PD-L1 (durvalumab, Solid tumours N = 1,038 • Dose Escalation: 5 cohorts at Q2W and 1 cohort at Q3W • Safety • FPD: Q3 2012 MEDI4736) • Dose Expansion: 16 tumour type cohorts at the Q2W • Optimal biologic dose • LPCD: Q4 2015 NCT01693562 MTD defined during dose escalation; one cohort at • Secondary endpoints include PK, • Estimated top-line results: 2017 20mg Q4W immunogenicity and antitumour activity Global trial – eight countries

Phase I PD-L1, azacitidine Myelodysplastic N = 41 Dose-escalation and dose-expansion trial • Safety and tolerability of • FPD: Q2 2014 (MEDI4736, Vidaza) syndrome • Arm 1: MEDI4736 IV monotherapy and combination • LPCD: Q2 2015 NCT02117219 • Secondary endpoints include • Estimated top-line results: 2017 Global trial – four countries duration of response, PFS and OS

95 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune + tremelimumab (CTLA-4 mAb) Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase Ib/II Gastric or GEJ N = 174 • Arm A: durvalumab + tremelimumab 2L • Safety & tolerability, ORR, PFS • FPD: Q2 2015 adenocarcinoma • Arm B: durvalumab 2L • Secondary endpoints include DCR, OS, • LPCD: 2017 NCT02340975 • Arm C: tremelimumab 2L DoR, PD-L1 Expression • Estimated top-line results: 2017 • Arm D: durvalumab + tremelimumab 3L

US and ROW trial centres

Phase Ib/II Hepatocellular Carcinoma N = 129 • Arm A: durvalumab + tremelimumab • Safety & tolerability, ORR, PFS • FPD: Q4 2015 • Arm B: durvalumab 2L • Secondary endpoints include DCR, OS, • LPCD: 2018 NCT02519348 • Arm C: tremelimumab 2L DoR, PD-L1 Expression • Estimated top-line results: 2018

Phase Ib Non-small cell lung cancer N = 388 • Dose Escalation: minimum 5 cohorts exploring various treme • Safety • FPD: Q4 2013 (Immunotx naïve and Q4W and MEDI4736 IV Q4W dose combinations, higher dose • Optimal biologic dose for the • LPCD: H2 2016 NCT02000947 Immunotx pretreated patient levels and alternate Q2 schedule added with amendment combination • Estimated top-line results: 2018 cohorts) • Dose Expansion: MTD for the combination in escalation to be • Secondary endpoints include Antitumour explored in expansion activity, PK and immunogenicity

North American trial centres, exploration of ex-US countries for expansion into EU and ROW

Phase I Solid tumours (Basket trial) N = 393 • Dose Exploration: 2 cohorts exploring various Q4W treme and • Safety & tolerability • FPD: Q4 2014 MEDI4736 dose combinations and 2 cohorts exploring various • Optimal biologic dose for the • LPCD: H2 2016 NCT02261220 Q2W treme and MEDI4736 dose combinations combination • Estimated top-line results: 2018 • Dose Expansion: MTD for the combination in escalation to be • Secondary endpoints include Antitumour explored in expansion cohorts specific for each of 7 tumour activity, PK/PD and immunogenicity types

North American trial centres

Phase I Squamous Cell Carcinoma of N = 69 • Arm A: treatment-naïve, PD-L1+, combo • Safety & tolerability • FPD: Q4 2014 the Head & Neck • Arm B: treatment-naïve, PD-L1-, combo • Secondary endpoints include OR, DC, • LPCD: Q1 2016 NCT02262741 • Arm C: PD-1/PD-L1 refractory, combo DoR, PFS, OS, PK/PD, immunogenicity • Estimated top-line results: 2017 and biomarkers North American trial centres

96 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) Early development - MedImmune + Iressa (gefitinib) Non-small cell lung cancer (NSCLC)

Trial phase Patient population Number of patients Design Endpoints Status

Phase I NSCLC N = 36 Escalation phase • Safety • FPD: Q2 2014 (Escalation phase) Standard 3+3 design with 28 days DLT period • Optimal biologic dose for the • LPCD: Q2 2015 NCT02088112 • Iressa (QD) + MEDI4736 IV combination • Estimated top-line results: 2017 EGFR M+ NSCLC naïve to • Secondary endpoints include tumour EGFR-TKI therapy Expansion phase response (CR, PR, SD, PD), Objective (Expansion phase) • Iressa (QD) + MEDI4736 IV recommended dose response rate, disease control rate, progression-free survival, Global trial – three countries immunogenicity, pharmacokinetics, pharmacodynamics

97 Lifecycle management Late-stage development Early development - IMED Durvalumab (MEDI4736; PD-L1 mAb) + Tafinlar Early development - MedImmune (dabrafenib)/ Mekinist (trametinib) Melanoma

Trial phase Patient population Number of patients Design Endpoints Status

Phase I/II Metastatic or unresectable N = 69 Dose Escalation: • Safety • FPD: Q1 2014 melanoma • Cohort A • Optimal biologic dose for the • LPCD: Q2 2015 NCT02027961 dabrafenib 150mg BiD/ trametinib 2mg QD/ MEDI4736 IV combination • Estimated top-line results: 2017 BRAF mutation+ • Cohort B • Secondary endpoints include Objective (Cohort A) trametinib 2mg QD/ MEDI4736 IV Response and Disease Control, • Cohort C Duration of Response, Progression-free BRAF wild type trametinib 2mg QD/ MEDI4736 IV Survival and OS, Pharmacokinetics and (Cohorts B&C) immunogenicity Dose Expansion: • Each cohort will be expanded at the MTD to enroll a total of 20 subjects per cohort

Global trial – two countries

98 Lifecycle management Late-stage development Early development - IMED MEDI0680 (PD-1 mAb) + durvalumab (MEDI4736) Early development - MedImmune Advanced malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced malignancies N = 150 Dose-escalation phase • Safety • FPD: Q2 2014 • MEDI4736 IV + MEDI0680 IV • Determination of MTD • LPCD: Q3 2015 NCT02118337 • Secondary endpoints include tumour • Estimated top-line results: 2018 Dose-expansion phase at selected dose from dose-escalation response such as objective response phase rate, disease control rate, progression- • MEDI4736 IV + MEDI0680 IV recommended dose free survival, duration of response, OS, immunogenicity, pharmacokinetics, pharmacodynamics

99 Lifecycle management Late-stage development Early development - IMED MEDI0562 (OX40 mAb) Early development - MedImmune MEDI0562 (OX40 mAb) + durvalumab (MEDI4736; PD-L1) or tremelimumab (CTLA-4 mAb) Advanced malignancies

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase I OX40 (MEDI0562) Advanced malignancies N = 196 Dose-escalation phase • Safety • FPD: Q1 2015 • MEDI0562 IV • Determination of MTD • LPCD: 2017 NCT02318394 • Secondary endpoints include • Estimated top-line results: 2017 Dose-expansion phase preliminary antitumour activity, • MEDI0562 IV recommended dose pharmacokinetics, biomarker activity, and immunogenicity

Phase I OX40 (MEDI0562) + Advanced malignancies N = 324 • ARM A: MEDI0562 IV + durvalumab IV • Safety • FPD: Q2 2016 NCT02705482 durvalumab (MEDI4736; • ARM B: MEDI0562 IV + tremelimumab IV • Secondary endpoints include • LPCD: 2018 PD-L1) preliminary antitumour activity, pharmacokinetics, and immunogenicity

100 Lifecycle management Late-stage development Early development - IMED MEDI6383 (OX40 agonist) + durvalumab Early development - MedImmune (MEDI4736; PD-L1 mAb) Advanced malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced malignancies N = 212 Dose-escalation phase • Safety • FPD: Q2 2015 • MEDI6383 IV • Determination of MTD • LPCD: H2 2016 NCT02221960 • MEDI6383 IV + MEDI4736 IV • Secondary endpoints include preliminary • Estimated top-line results: 2018 antitumour activity, pharmacokinetics, Biomarker activity, and immunogenicity Dose-expansion phase • MEDI6383 IV recommended dose • MEDI6383 IV + MEDI4736 IV recommended dose

US-only trial

101 Lifecycle management Late-stage development Early development - IMED Inebilizumab (MEDI-551, CD19 mAb) Early development - MedImmune Haematological malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase II Adults with relapsed or N = 170 • Arm 1: MEDI-551 dose level 1 and ICE/DHAP • ORR, including Complete Response • FPD: Q1 2012 refractory B-cell diffuse large • Arm 2: MEDI-551 dose level 2 and ICE/DHAP (CR) or Partial Response (PR) • LPCD: Q1 2016 NCT01453205 B-cell lymphoma • Arm 2: Rituxan + ICE/DHAP • Estimated top-line results: 2018

Open-label trial

Phase I Adults with relapsed or N = 18 • Dose-escalation trial IV • MTD and efficacy • FPD: Q2 11 refractory B-cell malignancies • LPCD: Q3 2015 NCT01957579 Conducted in Japan • Top-line results: Q3 2015

102 Lifecycle management Late-stage development Early development - IMED MEDI1873 (GITR agonist) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Adult subjects with select N = 42 Dose-escalation phase • Safety • FPD: Q4 2015 advanced solid tumours • MEDI1873 IV • Determination of MTD • LPCD: H2 2016 NCT02583165 US trial centres • Secondary endpoints include PK/PD, • Estimated top-line results: 2019 preliminary antitumour activity, pharmacokinetics, Pharmacodynamics, and immunogenicity

103 Lifecycle management Late-stage development Early development - IMED MEDI4276 (HER2 ADC mAb) Early development - MedImmune Advanced malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced HER2+ metastatic Dose escalation • First-time-in-human Phase 1, multi-centre, open-label, single- • Primary: Safety • FPD: Q4 2015 breast and gastric cancer N = 21-36 arm, dose-escalation, and dose-expansion trial for adult • LPCD: 2017 NCT02576548 subjects • Secondary endpoints include anti- • Estimated top-line results: 2018 Dose expansion tumour activity, overall response, N = 80 disease control, PFS, OS and change from baseline tumour size

104 Lifecycle management Late-stage development Early development - IMED MEDI9197 (TLR7/8 agonist) Early development - MedImmune Solid tumours

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced solid tumour N = 45 Dose-escalation phase • Safety • FPD: Q4 2015 malignancies readily • MEDI9197 IT • Determination of MTD • LPCD: 2017 NCT02556463 accessible for injection • Secondary endpoints include: • Estimated top-line results: 2018 – Objective response, disease control and duration of response . US trial centres- Ex US under evaluation – Intra-tumoural and systemic PK and PD profiles/relationships

105 Lifecycle management Late-stage development Early development - IMED MEDI9447 (CD73 mAb) + durvalumab Early development - MedImmune (MEDI4736; PD-L1 mAb) Advanced malignancies

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Advanced malignancies N = 132 Dose-escalation phase • Safety • FPD: Q3 2015 • MEDI9447 IV • Determination of MTD • LPCD: 2018 NCT02503774 • MEDI9447 IV + durvalumab IV • Secondary endpoints include PK/PD, • Estimated top-line results: 2018 preliminary anti-tumour activity, pharmacokinetics, Pharmacodynamics, Dose—expansion phase and immunogenicity • MEDI9447 IV recommended dose • MEDI9447 IV recommended dose + Durvalumab IV

US and Australian trial centres

106 Lifecycle management Late-stage development Early development - IMED Other biologics Early development - MedImmune Solid tumours

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase I/II Anti-IGF ligand mAb Patients with HR+ N = 176 • Arm 1: MEDI-573 IV and Aromatase Inhibitor • PFS • FPD: Q2 2012 (MEDI-573) HER2-, 1L, metastatic • Arm 2: Aromatase Inhibitor alone • Retrospective evaluation of predictive • LPCD: Q2 2013 NCT01446159 breast cancer taking biomarker +ve subgroups • Estimated top-line results: 2017 aromatase inhibitors Open label trial

Phase I Anti-Ang2 mAb Solid tumours and N = 25 • MEDI3617 Dose Escalation • Safety and tolerability • FPD: Q4 10 (MEDI3617) ovarian cancer • LPCD: Q2 2015 NCT01248949 N = 16 • MEDI3617 + bevacizumab dose escalation, • Top-line results: Q3 2015 administered Q3W, IV (US only) (completed) N = 13 • MEDI3617 + paclitaxel dose escalation, IV (US only)

N = 7 • MEDI3617 + carboplatin + paclitaxel dose escalation, IV (US only)

N = 27 • MEDI3617 + bevacizumab dose escalation, administered Q2W , IV (US only)

N = 17 • MEDI3617 single-agent expansion in ovarian cancer patients, IV (US only)

N = 15 • MEDI3617 + bevacizumab dose expansion in recurrent malignant glioma • US-only trial centres

107 Lifecycle management Late-stage development Early development - IMED Other biologics Early development - MedImmune Solid tumours

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase I Anti-CEA BiTE mAb Adults with N = 51 max • Dose-escalation (3+3), IV • MTD and safety profile • FPD: Q1 11 (MEDI-565) gastrointestinal (GI) • LPCD Q3 2014 NCT01284231 adenocarcinoma with • Top-line results: Q1 2015 completed no available standard or Partnered curative treatments.

Refractory pancreatic, colorectal and gastro- N = 60 max, • Dose expansion trial, IV esophageal cancers 20 in each cohort

Phase I Anti-DLL4 mAb Adults with advanced N = up to 28 • Dose-escalation trial (3+3); IV • MTD and safety profile • FPD: Q2 2012 (MEDI0639) solid tumours including • LPCD: Q2 2015 NCT01577745 SCLC • Estimated top-line results: H2 2016

108 Lifecycle management Late-stage development Early development - IMED Vaccine biologics Early development - MedImmune Influenza vaccines

Trial phase Compound Patient population Number of patients Design Endpoints Status

Phase III MEDI3250 Children 2 to 6 years N = 100 • Open-label • Safety and tolerability • FPD: Q4 2014 FluMist of age • Route of administration: intranasal • LPCD: Q1 2015 NCT02269488 • Top-line results: Q1 2015 (completed)

Phase III MEDI3250 Children 7 through 18 N = 1,008 • Randomised, double-blind placebo-controlled • Efficacy assessed by incidence of • FPD: Q4 2014 FluMist Quadrivalent years of age • Route of administration: intranasal laboratory-confirmed influenza-like • LPCD: Q4 2014 NCT02269475 illness in the two treatment arms • Top-line results: Q2 2015 (completed) • Safety and tolerability

109 Lifecycle management Late-stage development Early development - IMED Other biologics Early development - MedImmune Infections

Trial phase Compound Patient population Number of patients Design Endpoints Status Phase II Anti-Staph AT Intubated ICU N = 462 • Placebo-controlled, single-dose, dose-ranging • Efficacy and Safety • FPD: Q4 2014 (MEDI4893) • Route of administration: intravenous • LPCD: 2017 EudraCT 2014-001097-34 • Estimated top-line results: 2017

Phase IIb RSV sF+GLA-SE Adults ≥ 60 yrs N = 1,901 • Randomised, Double-blind trial • Efficacy • FPD: Q3 2015 (MEDI7510) • Route of administration: intramuscular • LPCD: H2 2016 NCT02508194 • Estimated top-line results: 2017

Phase Ib N = 264 • Double blind, randomised, placebo and active • Safety and tolerability • FPD: Q1 2015 controlled cohort escalation trial • Humoral and cell-mediated immune • LPCD: Q1 2015 NCT02289820 • Route of administration: intramuscular responses • Top-line results: Q1 2016

Phase Ia N = 144 • Double blind, randomised, placebo and active • Safety and tolerability • FPD: Q2 2014 controlled cohort escalation trial • Humoral and cell-mediated immune • LPCD: Q2 2014 NCT02115815 • Route of administration: intramuscular responses • Top-line results: Q2 2015 • Complete

Phase Ib/IIa Anti-RSV mAb-YTE 32-35 WK GA infants N = 89 • Randomised, Double-blind, Placebo-controlled, • Evaluate Safety, Tolerability, PK and • FPD: Q1 2015 (MEDI8897) Dose-escalation trial ADA • LPCD: Q3 2015 NCT02290340 • Route of administration: IM • Estimated top-line results: H2 2016

Phase Ia Healthy adults N = 136 • Randomised, Double-blind, Placebo-controlled, • Evaluate Safety, Tolerability, PK and • FPD: Q2 2014 Dose-escalation trial ADA • LPCD: Q2 2014 NCT02114268 • Route of administration: IV and IM • Top-line results: Q2 2015 (completed)

Phase Ib/IIa Anti-influenza A Adults N = 160 • Randomised, Partial Double-blind, Single Dose, • Evaluate Safety in Adults with Acute, • FPD: Q4 2015 mAb (MEDI8852) Active-controlled, Dose Ranging trial Uncomplicated Influenza • LPCD: H2 2016 NCT02603952 • Route of administration: intravenous • Estimated top-line results: Q2 2016

Phase I Healthy adults N = 40 • Double-blind, Single-dose, Placebo-controlled, • Evaluate the Safety and • FPD: Q1 2015 Dose-escalation trial Pharmacokinetics • LPCD: Q1 2015 NCT02350751 • Route of administration: intravenous • Top-line results: Q2 2015 • Complete

Phase I Anti-Pseudomonas Healthy adults N = 56 • Randomised, Double-blind, Placebo-Controlled, • Evaluate the Safety, Tolerability, and • FPD: Q3 2014 A mAb (MEDI3902) Dose-Escalation trial Pharmacokinetics • LPCD: Q1 2015 NCT02255760 • Route of administration: intravenous • Top-line results: Q2 2015 • Complete

Phase II Intubated ICU N = 429 • Placebo-controlled, single-dose, dose-ranging • Efficacy and Safety • FPD: H1 2016 • Route of administration: intravenous/ • LPCD: 2018 NCT02696902 • Estimated top-line results: 2018

110 Lifecycle management Late-stage development Early development - IMED MEDI1814 (amyloid beta mAb) Early development - MedImmune Alzheimer’s disease

Trial phase Patient population Number of patients Design Endpoints Status

Phase I Alzheimer’s disease & healthy N = 121 • SAD & MAD • Safety, tolerability • FPD: Q2 2014 elderly • Up to 10 iv cohorts are planned vs placebo • LPCD: H2 2016 NCT02036645 • 2 SC cohorts are planned vs placebo • Estimated top-line results: H2 2016

US only

111 Clinical trials appendix Q1 2016 update